Clinical trial register · United States · industry-sponsored

Clinical Trials in Illinois, 2026

Every industry-sponsored study on the ClinicalTrials.gov registry that lists a US site and is open, about to open, active-but-closed, or enrolling by invitation. This deliberately excludes academic and other non-industry sponsors — the full US registry across all sponsors runs to over 22,000 recruiting studies alone.

Download CSV

Source: ClinicalTrials.gov. Complete coverage of the industry-sponsored slice — all 9144 matching records are in this view (non-industry sponsors are out of scope by design, not truncated). Synced 16 Oct 2026, 03:16 UTC

9144

Studies in scope

industry-sponsored, all four open statuses

4957

Recruiting now

open to new participants

2196

Lead sponsors

across recruiting studies

Top states

California 5309 Florida 4445 Illinois 2491 Georgia 2363 Arizona 2246

Trials with a site in Illinois

Status

Study

Lead sponsor

Phase

Enrol

US states

Start

Not yet open

FGF-1 for Intramuscular Injection for the Treatment of Peripheral Arterial Disease

NCT00424866Peripheral Arterial Disease, Stenosis, Intermittent Claudication

Venturis Therapeutics, Inc.

Phase 1/2

Illinois

2028-10-15

Not yet open

A Study to Compare the Efficacy and Safety of BMS-986353 (Zolacabtagene- Autoleucel / Zola-cel), CD19-CAR T Cells, Versus Standard of Care in Participants With Active Systemic Sclerosis

NCT07335562Systemic Sclerosis

DrugsZola-cel·Nintedanib·Tocilizumab·Fludarabine

Juno Therapeutics, Inc., a Bristol-Myers Squibb Company

Phase 3

Arizona, Colorado, Florida, Georgia, Illinois, Massachusetts, Michigan, Minnesota

2027-02-03

Not yet open

A Phase II Study of Basmisanil in Children and Adolescents With Dup15q Syndrome

NCT07846215Dup15Q Syndrome

Newleos Therapeutics, Inc.

Phase 2

Illinois

2026-12-01

Recruiting

A Sequential Phase 2/3 Study of APL2 in Patients With Focal Segmental Glomerulosclerosis

NCT07213960FSGS

Apellis Pharmaceuticals, Inc.

Phase 2/3

270

Illinois, New York

2026-12

Not yet open

A Study to Evaluate Adverse Events and Change in Disease Activity With Injected Etentamig Plus Oral Pomalidomide Versus Standard Therapies in Adults With Relapsed or Refractory Multiple Myeloma

NCT07728188Relapsed or Refractory Multiple Myeloma

DrugsEtentamig·Teclistamab·Carfilzomib·Pomalidomide

AbbVie

Phase 3

520

Arizona, California, Colorado, District of Columbia, Florida, Georgia, Illinois, Massachusetts

2026-11-30

Not yet open

A Study to Assess The Safety and Tolerability of Pumitamig-Based Therapy Administered Before Surgery in Participants With Early-Stage Non-Small Cell Lung Cancer (ROSETTA Lung-220)

NCT07871214Early-Stage Non-Small Cell Lung Cancer

DrugsPumitamig·Pemetrexed·Paclitaxel·Cisplatin

Bristol-Myers Squibb

Phase 2

California, Florida, Illinois, Massachusetts, Oregon, Pennsylvania, Tennessee, Texas

2026-11-30

Recruiting

A Trial to Evaluate Ovarian Suppression Following Subcutaneous ZOLADEX 10.8 mg in Premenopausal Women With Early-stage and Advanced HR+ Breast Cancer

NCT07310420Advanced Breast Cancer, Early Breast Cancer

DrugZoladex

TerSera Therapeutics LLC

Phase 1

176

Arkansas, District of Columbia, Florida, Georgia, Illinois, Iowa, Louisiana, Michigan

2026-10-30

Recruiting

A Study to Evaluate the Efficacy and Safety of Subcutaneous Nomlabofusp in Subjects With Friedreich's Ataxia

NCT07778836Friedreich Ataxia, Friedreich's Ataxia

DrugNomlabofusp

Larimar Therapeutics, Inc.

Phase 3

150

Florida, Illinois, New Jersey, Texas

2026-10-26

Not yet open

A Research Study to Look at How Well Zenagamtide Works Compared to Placebo in People With Established Atherosclerotic Cardiovascular Disease and Either Overweight or Obesity

NCT07861100Cardiovascular Risk, Obesity

DrugZenagamtide

Novo Nordisk A/S

Phase 3

8,500

Alabama, Arizona, California, Connecticut, Florida, Georgia, Idaho, Illinois

2026-10-26

Not yet open

A Study to Learn About the Study Medicine Called Ponsegromab in Adults With Lung Cancer-Associated Significant Body Weight Loss

NCT07663630Non-small Cell Lung Cancer (NSCLC), Cachexia

DrugPonsegromab

Pfizer

Phase 1

Illinois, Texas

2026-10-23

Not yet open

DAREON®-36: A Study to Test Obrixtamig in Combination With ZL-1310 in People With Advanced Small Cell Lung Cancer or Other Neuroendocrine Cancers

NCT07707895Small Cell Lung Cancer, Large Cell Neuroendocrine Lung Carcinoma, Extrapulmonary Neuroendocrine Carcinoma of Small Cell Histology, Extrapulmonary Neuroendocrine Carcinoma of Large Cell Histology

DrugsZL-1310·Obrixtamig·Atezolizumab

Boehringer Ingelheim

Phase 1/2

District of Columbia, Florida, Illinois, Kentucky

2026-10-19

Not yet open

A Study to Evaluate the Analgesic Properties of Topically Applied Menthol in Marathon Participants

NCT07873242Muscle Soreness

Reckitt Benckiser Healthcare (UK) Limited

Observational

600

Illinois

2026-10-11

Recruiting

Effect of a Dietary Supplement Versus Placebo on Serum PFAS Levels in Male Firefighters

NCT07846371Environmental Exposure, PFAS Exposure

Cambiotics ApS

Not applicable

Illinois

2026-10-08

Recruiting

A Study to Investigate CEA-PRIT 2.0 in Participants With Metastatic Colorectal Cancer (mCRC)

NCT07416552Metastatic Colorectal Cancer

Hoffmann-La Roche

Phase 1

180

Illinois, Missouri, Nebraska, Texas, Wisconsin

2026-10-06

Not yet open

A Study of KarXT + KarX-EC for Treatment of Irritability in Children and Adolescents With Autism Spectrum Disorder

NCT07285798Irritability Associated With Autism Spectrum Disorder

DrugsKarX-EC·KarXT

Bristol-Myers Squibb

Phase 3

176

Arizona, California, Connecticut, Florida, Georgia, Illinois, Massachusetts, Missouri

2026-10-02

Recruiting

Study of a Recombinant Spike COVID-19 Vaccine With Matrix-M in Older Adults and People at Increased Risk of Severe COVID-19

NCT07861542COVID-19

Sanofi

Phase 4

660

California, Florida, Georgia, Illinois, Iowa, Kansas, Louisiana, Maryland

2026-10-01

Not yet open

A Prospective, Randomized Multicenter Clinical Trial of the TricValve® Transcatheter Bicaval Valve System in Subjects With Severe Tricuspid Regurgitation.

NCT06458907Tricuspid Valve Disease, Heart Valve Diseases, Cardiovascular Diseases, Heart Failure

P+F Products + Features USA Inc.

Not applicable

780

Alabama, Arizona, California, District of Columbia, Florida, Illinois, Indiana, Kansas

2026-10

Not yet open

Signatera Assessment in Early-Stage Endometrial Cancer

NCT07339384Endometrial Cancer

Natera, Inc.

Not applicable

1,010

Alabama, California, Florida, Illinois, Minnesota, New York, North Carolina, Ohio

2026-10

Recruiting

Study of EO2002 in Subjects With Corneal Edema Secondary to Corneal Endothelial Dysfunction

NCT07729137Corneal Edema, Fuchs, Fuchs Dystrophy, Fuchs' Endothelial Dystrophy

Emmecell

Phase 2

121

California, Florida, Georgia, Illinois, Indiana, Kansas, Minnesota, Missouri

2026-10

Recruiting

To Investigate the Efficacy of Treatment With Oral NA-921 (Bionetide) Versus Placebo in Females With Rett Syndrome

NCT06840496Rett Syndrome

Biomed Industries, Inc.

Phase 3

210

Arizona, California, Colorado, Florida, Illinois, Maryland, Massachusetts, New York

2026-09-30

Not yet open

Neoadjuvant Pembrolizumab and Porustobart in Resectable pMMR/MSS Colon Cancer

NCT07808151Colon Cancer, Microsatellite Stable (MSS) Colon Cancer, Proficient Mismatch Repair (pMMR) Colon Cancer

DrugsPorustobart·Keytruda·Pembrolizumab

Solstice Oncology, Inc.

Phase 2

100

California, Florida, Illinois, Maryland, Massachusetts, New York, Ohio, Tennessee

2026-09-30

Not yet open

BrainProtect-guided, Real-time Cerebral Autoregulation Monitoring and Protection of Brain During Cardiac Surgery With Cardiopulmonary Bypass Requiring Heart-lung Machine

NCT07872982Cerebral Autoregulation Impairment, Postoperative Cognitive Dysfunction, Postoperative Delirium

Scienceforbrain, UAB

Not applicable

304

Illinois

2026-09-30

Recruiting

A Study to Evaluate CRB-701 Compared to Investigator's Choice Therapy in Previously Treated Oropharyngeal Squamous Cell Carcinoma

NCT07768189Oropharyngeal Carcinoma (OPC)

DrugsCRB-701·Cetuximab·Docetaxel

Corbus Pharmaceuticals Inc.

Phase 3

260

Alabama, Arizona, California, Colorado, Connecticut, Delaware, Florida, Illinois

2026-09-29

Recruiting

Efficacy, Safety, and Pharmacokinetics of Tirzepatide (LY3298176) Once Weekly Versus Placebo in Pediatric Participants 6 to Less Than 12 Years of Age Who Have Obesity (ADVANCE-SURMOUNT-KIDS)

NCT07817875Obesity

DrugTirzepatide

Eli Lilly and Company

Phase 3

150

Arizona, California, Colorado, Connecticut, Florida, Georgia, Illinois, Indiana

2026-09-25

Recruiting

ACX-362E [Ibezapolstat] for Oral Treatment of Recurrent Clostridioides Difficile Infection

NCT07513285Clostridium Difficile Infection Recurrence

Acurx Pharmaceuticals Inc.

Phase 2

California, Connecticut, Florida, Georgia, Idaho, Illinois, Massachusetts, Michigan

2026-09-25

Recruiting

A Research Study Investigating How Well the Medicine Zenagamtide Helps People With Excess Body Weight Lose Weight Compared to Semaglutide

NCT07668414Overweight, Obesity

DrugsZenagamtide·Semaglutide

Novo Nordisk A/S

Phase 3

650

California, District of Columbia, Florida, Georgia, Illinois, Indiana, Louisiana, Missouri

2026-09-22

Recruiting

An Open-Label, Safety and Efficacy Study of Cebranopadol in Participants With Acute Pain With Surgical or Non-Surgical Origin

NCT07845071Pain

DrugCebranopadol

Adneuris Therapeutics, Inc.

Phase 3

160

Arizona, California, Colorado, Georgia, Illinois, Maryland, New Jersey, Oklahoma

2026-09-22

Not yet open

A Single Ascending Dose, and Food Effect Study of ABBV-7828 in Healthy Adults

NCT07856706Healthy Subjects

AbbVie

Phase 1

Illinois

2026-09-21

Recruiting

A Phase 3 Trial for Intravitreal Injection of 4D-150 in Adults With Diabetic Macular Edema (DME).

NCT07867080Diabetic Macular Edema (DME)

Drug4D-150 IVT

4D Molecular Therapeutics

Phase 3

514

Arizona, California, Colorado, Connecticut, Florida, Illinois, Indiana, Maryland

2026-09-18

Recruiting

A Study to Evaluate the Safety and Efficacy of JZP926 Capsule for the Treatment of Juvenile Myoclonic Epilepsy

NCT07723963Juvenile Myoclonic Epilepsy

DrugCannabidiol

Jazz Pharmaceuticals

Phase 2/3

260

Arizona, California, Connecticut, Florida, Georgia, Hawaii, Idaho, Illinois

2026-09-18

Recruiting

Research Study on How People With Type 2 Diabetes Tolerate Switching From Semaglutide to Cagrisema

NCT07817251Diabetes Mellitus, Type 2

DrugCagriSema

Novo Nordisk A/S

Phase 3

210

Arizona, California, Connecticut, Florida, Hawaii, Illinois, Iowa, Kansas

2026-09-16

Recruiting

Saruparib in Combination With Physician's Choice of ARPI in Patients With mHSPC Previously Treated With Docetaxel or 177Lu-PSMA Therapy Without Disease Progression and PSA ≥ 0.2 ng/mL (EvoPAR-PR05)

NCT07711002Metastatic Hormone-Sensitive Prostate Cancer (mHSPC)

DrugsSaruparib·Abiraterone·Darolutamide·Enzalutamide

AstraZeneca

Phase 3

1,330

Arkansas, California, Florida, Hawaii, Illinois, Iowa, Maryland, Michigan

2026-09-15

Recruiting

Observational, Non-interventional Biomarker and Endotyping Study

NCT07675265ARDS (Acute Respiratory Distress Syndrome)

Prenosis, Inc.

Observational

1,200

Illinois

2026-09-14

Recruiting

Effects of Continuous Yogurt Intake on Immunomodulatory Function and Subjective Health Status in Healthy U.S. Adults

NCT07799207Immune Function

Meiji Co., Ltd.

Not applicable

118

Illinois

2026-09-14

Not yet open

A Study of KarXT + KarX-EC for Treatment of Irritability in Children and Adolescents With Autism

NCT07284745Irritability Associated With Autism Spectrum Disorder

DrugsKarX-EC·KarXT

Bristol-Myers Squibb

Phase 3

176

Alabama, Arizona, California, Colorado, Florida, Georgia, Illinois, Kentucky

2026-09-11

Recruiting

A Study in Adults With Geographic Atrophy

NCT07606365Geographic Atrophy

DrugSTL303

Sitala Bio LTD

Phase 2

300

California, Colorado, Connecticut, Illinois, Maryland, Massachusetts, New York, Pennsylvania

2026-09-11

Recruiting

Transcatheter Tricuspid Valve Replacement With the Medtronic Intrepid™ Transcatheter Tricuspid Valve Replacement (TTVR) System in Severe Tricuspid Regurgitation

NCT07321899Severe Tricuspid Regurgitation

Medtronic Cardiovascular

Not applicable

1,186

Alabama, Arizona, California, Connecticut, Georgia, Illinois, Minnesota, New York

2026-09-11

Recruiting

Evaluation of Approved Contact Lenses (CR-6657)

NCT07819305Visual Acuity

Johnson & Johnson Vision Care, Inc.

Not applicable

150

Florida, Illinois, New York, Ohio, Tennessee, Texas, Virginia

2026-09-10

Recruiting

Device for Treating Generalized Anxiety

NCT07819773Generalized Anxiety Disorder (GAD)

BTL Industries Ltd.

Not applicable

Colorado, Illinois, Indiana

2026-09-09

Recruiting

A Phase 3 Study of INCA033989 Versus Best Available Therapy in Participants With Essential Thrombocythemia

NCT07623200Essential Thrombocythemia

DrugINCA033989

Incyte Corporation

Phase 3

426

Alabama, Arizona, California, Colorado, District of Columbia, Florida, Illinois, Kansas

2026-09-08

Recruiting

A Study to Assess the Safety, Tolerability, and Immunogenicity of 3 Lots of a Multivalent Pneumococcal Conjugate Vaccine Administered to Adults

NCT07794748Pneumococcal Disease

DrugPrevnar 20

Pfizer

Phase 3

4,670

Alabama, California, Connecticut, Florida, Georgia, Hawaii, Illinois, Iowa

2026-09-08

Recruiting

Study of Izalontamab Brengitecan (BMS-986507) in Combination With Osimertinib Versus Osimertinib Monotherapy or Osimertinib in Combination With Platinum-based Chemotherapy for EGFRmt Non-small Cell Lung Cancer (IZABRIGHT-Lung02)

NCT07680790Non-Small Cell Lung Cancer

DrugsIza-bren·Osimertinib·Pemetrexed·Cisplatin

Bristol-Myers Squibb

Phase 3

850

California, Colorado, Florida, Illinois, Maryland, Minnesota, Missouri, Nebraska

2026-09-08

Not yet open

A Prospective Study Comparing CSF Shunt Flow Between "Virtual Off" and "Flow Permissive" Shunt Valve Settings Using a Wireless, Noninvasive Shunt Flow Sensor

NCT07815314Hydrocephalus

Rhaeos, Inc.

Not applicable

Illinois

2026-09-08

Recruiting

A Study to Evaluate the Efficacy and Safety of CBL-514 Injection for Reducing Subcutaneous Fat

NCT07140939Subcutaneous Fat

DrugCBL-514

Caliway Biopharmaceuticals Co., Ltd.

Phase 3

320

California, Florida, Illinois, Louisiana, Maryland, Nebraska, New Jersey, New York

2026-09-01

Recruiting

A Phase III Study to Evaluate the Effect of Balcinrenone/Dapagliflozin in Patients With CKD Stage 3b and 4 (BalanceD-CKD)

NCT07624305Renal Insufficiency, Chronic

DrugsBalcinrenone/dapagliflozin·Dapagliflozin

AstraZeneca

Phase 3

2,800

Alabama, Arizona, Arkansas, California, District of Columbia, Florida, Georgia, Illinois

2026-09-01

Not yet open

Hypoxic Red Blood Cells in Sickle Cell Anemia

NCT06743113Sickle Cell Anaemia, Sickle Cell Anemia Crisis, Sickle Cell Anemia in Children, Sickle Cell Anemia (HbSS, or HbSβ-thalassemia0)

Hemanext

Not applicable

Connecticut, Georgia, Illinois, Maryland, Pennsylvania

2026-09-01

By invitation

OsteoFlo HydroFiber Ambispective Evaluation

NCT07784673OsteoFlo HydroFiber

SurGenTec LLC

Observational

100

Illinois, Indiana

2026-09-01

Not yet open

A Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1283 in Participants ≥6 Months to <12 Years of Age

NCT07808697SARS-CoV-2

DrugsMNEXSPIKE·Spikevax

ModernaTX, Inc.

Phase 2

300

California, Florida, Illinois, Michigan, Ohio, Texas, Utah, Virginia

2026-09-01

Recruiting

Evaluation of the Efficacy, Safety, and Tolerability of PL-14 Allergy Blocker Compared to Saline Spray in Patients With Seasonal Allergic Rhinitis

NCT07588672Seasonal Allergic Rhinitis (SAR), Allergic Rhinitis

Polyrizon Ltd.

Not applicable

120

Illinois, Missouri, New Jersey, Texas

2026-09-01

Recruiting

Redefine Study: A Study Evaluating the Efficacy, Safety, and Tolerability of COMP360 in Participants With Post-traumatic Stress Disorder

NCT07570654PTSD - Post Traumatic Stress Disorder, PTSD, PTSD Symptoms, PTSD, Post Traumatic Stress Disorder

COMPASS Pathways

Phase 2/3

300

Florida, Illinois, Minnesota, Nebraska, Nevada, New York

2026-09

Recruiting

MaioRegen Prime Study for the Treatment of Deep Osteochondral Lesion of the Knee

NCT07332182Osteochondral Lesions of the Knee Joint, Osteochondritis Dissecans (OCD), Early Osteoarthritis

Fin-Ceramica Faenza Spa

Not applicable

400

California, Colorado, Illinois, Michigan, Ohio, Oregon, Tennessee, Texas

2026-09

Recruiting

A Trial to Assess the Efficacy and Safety of Engasertib in Participants With Moderate to Severe Hereditary Hemorrhagic Telangiectasia (HHT)

NCT07743671Hereditary Hemorrhagic Telangiectasia

DrugEngasertib

Vaderis Therapeutics AG

Phase 3

240

Illinois, Indiana, Minnesota, Missouri

2026-09

Recruiting

Brexanolone Lifting Outcomes Of Moms

NCT07822321Depression, Postpartum, Postpartum Depression (PPD), Post-partum Depression, Postnatal Depression

Lipocine Inc.

Phase 3

120

Arizona, California, Colorado, Georgia, Idaho, Illinois, Louisiana, Nevada

2026-09

Not yet open

WATER IV PCa (AS Sub-study)

NCT07650448Localized Prostate Cancer

PROCEPT BioRobotics

Not applicable

333

Arizona, California, Colorado, Florida, Georgia, Idaho, Illinois, Maryland

2026-09

Recruiting

A Study of the Safety and Efficacy of Prime Editing (PM577) in Participants With Wilson Disease (WD)

NCT07748403Wilson Disease, Wilson's Disease, Wilsons Disease

Prime Medicine, Inc.

Phase 1/2

Connecticut, Illinois, Texas

2026-09

Recruiting

A Phase IIa Study of ICG318 CAR-T in Refractory Systemic Lupus Erythematosus With or Without Lupus Nephritis

NCT07328581Systemic Lupus Erythematosus (SLE), Lupus Nephritis (LN)

iCell Gene Therapeutics

Phase 2

Illinois, New York, Pennsylvania

2026-09

Recruiting

Study Evaluating the Efficacy and Safety of RAP-219 in Adult Participants With Focal Seizures

NCT07594119Focal Seizure, Epilepsy, Focal Epilepsy

DrugRAP-219

Rapport Therapeutics Inc.

Phase 3

312

Alabama, Arkansas, Colorado, Florida, Hawaii, Illinois, Nebraska, New York

2026-09

Recruiting

Rollover Study for Participants Who Have Completed a Previous Clinical Study With Anifrolumab (Saphnelo) and Clinically Benefited From Continued Treatment

NCT07691970Systemic Sclerosis Cutaneous Lupus E Myopathies Systemic Lupus Erythematosus

DrugAnifrolumab

AstraZeneca

Phase 3

1,072

Arizona, California, Florida, Illinois, Michigan, Minnesota, Nebraska, New York

2026-08-31

Recruiting

AMAZE 9: A Research Study Investigating How Well Zenagamtide Tablets Help People With Excess Body Weight Lose Weight

NCT07720271Overweight, Obesity

DrugZenagamtide

Novo Nordisk A/S

Phase 3

950

Alabama, California, Colorado, Florida, Georgia, Hawaii, Illinois, Indiana

2026-08-31

Recruiting

The Effects of Daily Supplementation of a Soluble Fiber on the Fecal Microbiota in Volunteers.

NCT07846254Healthy Volunteers

Roquette Freres

Not applicable

100

Illinois

2026-08-31

Recruiting

A Trial to Investigate PALI-2108 Versus Placebo in Participants With Moderately to Severely Active Ulcerative Colitis

NCT07845487Ulcerative Colitis (UC), Severe Ulcerative Colitis, Moderate Ulcerative Colitis

DrugPALI-2108

Palisade Bio

Phase 2

204

Arizona, California, Connecticut, Florida, Illinois, Louisiana, Mississippi, Missouri

2026-08-28

Recruiting

A 52-week Study of Remibrutinib in IgE-mediated Food Allergy

NCT07768371IgE-Mediated Food Allergy, Peanut Allergy, Cow Milk Allergy, Egg Allergy

DrugRemibrutinib

Novartis Pharmaceuticals

Phase 3

576

Alabama, Arizona, Arkansas, California, Colorado, Georgia, Illinois, Maryland

2026-08-27

Recruiting

Studying NMDA and Sigma-1 in Smoking Cessation Treatment (SUMMIT)

NCT07766655Smoking Cessation

DrugsDextromethorphan-bupropion·Bupropion

Axsome Therapeutics, Inc.

Phase 3

705

Arkansas, California, Florida, Georgia, Illinois, Indiana, Missouri, New York

2026-08-27

Recruiting

A Study of Clazakizumab (LY5724886) in Adults With Elevated hsCRP and at Increased Risk for Cardiovascular Event

NCT07783802Atherosclerosis, Cardiovascular Disease, Obesity, Hypertension

DrugClazakizumab

Eli Lilly and Company

Phase 2

120

Alabama, Arizona, California, Florida, Georgia, Illinois, Indiana, Massachusetts

2026-08-27

Recruiting

A Study of Orforglipron in Participants With Overweight at Risk of Development of Obesity-Related Complications or Progression to Class 1 Obesity

NCT07794579Overweight, Prediabetic State, Prehypertension, Obesity, Abdominal

DrugOrforglipron

Eli Lilly and Company

Phase 3

2,001

Alabama, Arizona, California, Connecticut, Florida, Georgia, Idaho, Illinois

2026-08-26

Recruiting

A Study to Evaluate the Safety and Pharmacokinetics of Multiple Doses Upadacitinib, Tofacitinib, and Baricitinib in Healthy Adult Volunteers

NCT07843693Healthy Volunteers

DrugsBaricitinib·Tofacitinib·Upadacitinib

AbbVie

Phase 1

Illinois

2026-08-26

Recruiting

A Study of the Long-term Safety and Efficacy of Danicamtiv in Adults With Symptomatic Genetic and Familial Dilated Cardiomyopathy

NCT07771465Symptomatic Genetic Dilated Cardiomyopathy (DCM)

DrugDanicamtiv

Kardigan, Inc.

Phase 3

332

Alabama, California, District of Columbia, Florida, Illinois, Louisiana, Maryland, Massachusetts

2026-08-26

Recruiting

A Study of EDG-15400 in Adults With Heart Failure With Preserved Ejection Fraction (EQUINOX-HFpEF)

NCT07795814Heart Failure With Preserved Ejection Fraction

Edgewise Therapeutics, Inc.

Phase 2

Alabama, Arkansas, California, Florida, Illinois, Indiana, Louisiana, Maryland

2026-08-25

Not yet open

A Phase III, Multicentre Study to Evaluate Consolidation Treatment With AZD0120 Compared With ASCT, in Participants With Newly Diagnosed Multiple Myeloma Who Are Transplant Eligible (DURGA-6).

NCT07735637Newly Diagnosed Multiple Myeloma (NDMM)

DrugsASCT·AZD0120·Melphalan·Lenalidomide

AstraZeneca

Phase 3

750

Florida, Georgia, Illinois, Michigan, Minnesota, Ohio, Texas, Washington

2026-08-25

Recruiting

A Phase 2a/b Study to Assess the Efficacy, Safety and Tolerability of DDY391 in Participants With Sjögren's Disease

NCT07737743Sjögren's Disease

DrugDDY391

Novartis Pharmaceuticals

Phase 2

344

Florida, Illinois, Oklahoma, Pennsylvania, Texas

2026-08-24

Recruiting

AMBITION 7: A Research Study Investigating How Well Zenagamtide Lowers Blood Sugar and Body Weight Compared to Insulin Glargine in People With Type 2 Diabetes and Increased Risk of Diseases That Affect the Heart and Blood Vessels Treated With 1-3 Other Diabetes Medications

NCT07797335Type 2 Diabetes, Cardiovascular Risk

DrugZenagamtide

Novo Nordisk A/S

Phase 3

1,778

Alabama, Arizona, California, Florida, Georgia, Idaho, Illinois, Indiana

2026-08-24

Recruiting

A Study to Evaluate Effect of AZD6234 as an Adjunct to Incretin-based Therapies in Adult Participants With Obesity or Overweight With Weight-related Comorbidity With or Without Type 2 Diabetes Mellitus

NCT07776509Obesity or Overweight, Weight-Related Comorbidity, With/Without Diabetes Mellitus, Type 2

DrugLenbelintide

AstraZeneca

Phase 3

500

California, Florida, Georgia, Illinois, Maryland, Missouri, Nevada, New Jersey

2026-08-24

Recruiting

A Study of Romiplostim Plus Predniso(lo)ne vs. Predniso(lo)ne Alone for the Treatment of Previously Untreated Primary Immune Thrombocytopenia (ITP)

NCT07700238Primary Immune Thrombocytopenia

DrugsPredniso(lo)ne·Nplate·Romiplostim

Amgen

Phase 3

126

California, Illinois, Virginia

2026-08-21

Recruiting

ORKA-002 Versus Placebo in Participants With Moderate-to-Severe Hidradenitis Suppurativa

NCT07783542Hidradenitis Suppurativa (HS)

DrugORKA-002

Oruka Therapeutics, Inc.

Phase 2

200

Alabama, California, Connecticut, Georgia, Illinois, Louisiana, Michigan, Minnesota

2026-08-21

Recruiting

Relapse Prevention Trial Evaluating KarXT Treatment in Schizophrenia

NCT07686263Schizophrenia

DrugKarXT

Karuna Therapeutics, Inc., a Bristol Myers Squibb company

Phase 3

472

Arkansas, California, Florida, Georgia, Illinois, Maryland, Ohio, Oklahoma

2026-08-20

Recruiting

PheCheck™ Validation Study

NCT07551921Phenylketonuria (PKU) and Hyperphenylalaninemia

Aptatek BioSciences, Inc

Observational

Illinois, Massachusetts

2026-08-20

Recruiting

A Study to Assess Adverse Events and How Oral ABBV-932 Moves Through the Body When Given With Oral Itraconazole in Adult Participants With Bipolar Disorder

NCT07071532Bipolar Disorder

DrugsABBV-932·Itraconazole

AbbVie

Phase 1

California, Illinois

2026-08-20

Recruiting

A Study to Evaluate Effect of AZD6234 in Adult Participants With Type 2 Diabetes Mellitus and Obesity or Overweight

NCT07784270Obesity or Overweight, Diabetes Mellitus, Type 2

DrugLenbelintide

AstraZeneca

Phase 3

1,500

Alabama, Arizona, Arkansas, California, Florida, Georgia, Illinois, Kansas

2026-08-20

Recruiting

A Study to Evaluate Effect of AZD6234 in Adult Participants With Obesity or Overweight With Weight-related Comorbidity Without Type 2 Diabetes Mellitus

NCT07784725Obesity or Overweight

DrugLenbelintide

AstraZeneca

Phase 3

2,500

Alabama, Arizona, California, Florida, Georgia, Illinois, Iowa, Michigan

2026-08-19

Recruiting

A Study of Brenipatide (LY3537031) in Adult Participants With Major Depressive Disorder

NCT07775300Depressive Disorder, Major

DrugBrenipatide

Eli Lilly and Company

Phase 3

1,000

Alabama, Arizona, California, Florida, Georgia, Illinois, Maryland, Massachusetts

2026-08-14

Recruiting

A Phase III Study to Assess the Effect of FDC Laroprovstat/Rosuvastatin Compared With Laroprovstat, Rosuvastatin and Placebo on LDL-C in LLT-naïve Patients.

NCT07619131Hypercholesterolaemia

DrugsRosuvastatin 1·Rosuvastatin 2

AstraZeneca

Phase 3

600

Alabama, Arizona, California, Colorado, Connecticut, Florida, Georgia, Illinois

2026-08-12

Recruiting

A Chronic Pain Master Protocol (CPMP): A Study of LY4065967 in Participants With Chronic Low Back Pain

NCT07641504Chronic Pain, Low Back Pain

DrugLY4065967

Eli Lilly and Company

Phase 2

150

Alabama, Arizona, California, Connecticut, Florida, Georgia, Illinois, Louisiana

2026-08-12

Not yet open

A Study on the Immune Response and Safety of an Investigational Combined Measles, Mumps, Rubella and Varicella Vaccine, When Given to Healthy Children 4 to 6 Years of Age

NCT07742644Measles, Mumps, Rubella, Varicella (Chickenpox)

GlaxoSmithKline

Phase 3

1,860

Arkansas, California, Florida, Idaho, Illinois, Kentucky, Louisiana, Missouri

2026-08-11

Recruiting

Study to Assess the Effect and Safety of ALV-100 on Maintenance of Weight Loss

NCT07837973Overweight , Obesity, Adults

DrugALV-100

Alveus Therapeutics, Inc.

Phase 2

220

Alabama, Arizona, California, Florida, Georgia, Illinois, Louisiana, Michigan

2026-08-10

Recruiting

A Study of Brenipatide (LY3537031) in Adult Participants With Moderate-to-Severe Chronic Obstructive Pulmonary Disease (COPD)

NCT07759245Pulmonary Disease, Chronic Obstructive

DrugBrenipatide

Eli Lilly and Company

Phase 2

606

Alabama, California, Colorado, Florida, Illinois, Indiana, Massachusetts, Michigan

2026-08-07

Recruiting

A Study to Measure Mirikizumab Levels in Breast Milk of Lactating Participants Receiving Mirikizumab Therapeutically for an Approved Indication

NCT07612267Lactation, Inflammatory Bowel Disease

DrugMirikizumab

Eli Lilly and Company

Phase 4

Illinois, Iowa, Maryland, New York, Ohio

2026-08-05

Recruiting

A Study to Assess the Tolerability of Ianalumab (VAY736) With Investigator's Choice Thrombopoietin Receptor Agonist (IC TPO-RA) in Patients With Primary Immune Thrombocytopenia (ITP)

NCT07421167Primary Immune Thrombocytopenia (ITP), Primary Evans Syndrome (ES)

DrugsTpo-Ra·Avatrombopag·Romiplostim·Eltrombopag

Novartis Pharmaceuticals

Phase 2

164

Arkansas, California, Connecticut, Florida, Illinois, Louisiana, Minnesota, Missouri

2026-08-04

Recruiting

A Research Study to See How Much CagriSema Lowers Blood Sugar and Body Weight Compared to Placebo in Children and Adolescents With Type 2 Diabetes

NCT07282613Diabetes Mellitus, Type 2

DrugCagriSema

Novo Nordisk A/S

Phase 3

Connecticut, Florida, Georgia, Illinois, Indiana, Iowa, Michigan, New York

2026-08-04

Recruiting

Safety and Efficacy of ABBV-295 in Adults With Obesity or Overweight With Weight-Related Comorbidities

NCT07752979Obesity, Overweight

DrugABBV-295

AbbVie

Phase 2

360

Alabama, Arizona, California, Florida, Idaho, Illinois, Kentucky, Mississippi

2026-08-04

Recruiting

A Research Study to Compare Two Different Versions of Injectable Cagrilintide and Placebo in People With Excess Body Weight

NCT07745504Overweight, Obesity

DrugCagrilintide

Novo Nordisk A/S

Phase 3

285

Georgia, Hawaii, Illinois, Indiana, Kentucky, North Carolina, South Carolina, Virginia

2026-08-04

Recruiting

A Long-Term Safety Study of Elismetrep (K-304) in the Acute Treatment of Migraine

NCT07674654Acute Migraine

DrugElismetrep

Kallyope Inc.

Phase 3

1,000

Alabama, Arizona, Arkansas, California, Colorado, Connecticut, Georgia, Illinois

2026-08-03

Recruiting

Study to Assess Safety and Immunogenicity of an Egg-based H5N8 Influenza Vaccine at Multiple Dose Levels Adjuvanted With Matrix-M in Healthy Participants 18 Years of Age and Above.

NCT07779408Healthy Volunteers, Influenza

Sanofi

Phase 1/2

640

Arizona, California, Florida, Georgia, Illinois, Kansas, New York, South Carolina

2026-08-03

Recruiting

Determine Maximum Tolerated Dose, Safety, and Tolerability of Rhenium (186Re) in Pediatric Recurrent, Refractory or Progressive Ependymoma and High-Grade Glioma

NCT07061626Ependymoma, High Grade Gliomas

DrugRhenium Liposome Treatment

Cerenome

Phase 1

Illinois

2026-08-01

Recruiting

Illuminate: A Clinical Study Evaluating CAR T Immune Cell Therapy (BCB-276) for Patients With Diffuse Intrinsic Pontine Glioma (DIPG).

NCT07680439Diffuse Intrinsic Pontine Glioma, DIPG, Brain Tumor, CNS Tumor

BrainChild Bio, Inc

Phase 2

California, Georgia, Illinois, Ohio, Pennsylvania, Washington

2026-08

Recruiting

Tempus Open Link for Individual Voices in Innovative Analytics Registry: Platform Protocol for Multimodal Real-World Evidence in Cancer

NCT07756034Cancer, Solid Tumor Cancer, Pediatric Acute Myeloid Leukemia, Hematologic Malignancies

Tempus AI

Observational

1,000

Illinois

2026-08

Recruiting

A Study to Investigate the Efficacy and Safety of Apraglutide Compared With Placebo in Adult Participants With Short Bowel Syndrome Associated With Intestinal Failure (SBS-IF)

NCT07742735Short Bowel Syndrome (SBS), SBS Associated With Intestinal Failure (SBS-IF)

DrugApraglutide

VectivBio AG

Phase 3

124

California, Colorado, District of Columbia, Florida, Illinois, Kentucky, Michigan, New York

2026-08

Recruiting

A Phase 2b Clinical Trial of YN001 in Adults With Coronary Atherosclerosis

NCT07521007Atherosclerosis, Coronary Artery Disease

Beijing Inno Medicine Co., Ltd.

Phase 2

456

Alabama, California, Florida, Georgia, Idaho, Illinois, Kansas, Missouri

2026-07-31

Recruiting

Study of Advanced Therapies for the Treatment of Adult Participants With Moderately to Severely Active Crohn's Disease or Ulcerative Colitis

NCT07697456Crohn's Disease, Ulcerative Colitis

DrugsABBV-701·Trosunilimab·Risankizumab

AbbVie

Phase 2

2,000

Alabama, Arizona, California, Colorado, Florida, Georgia, Idaho, Illinois

2026-07-31

Recruiting

A Study in Young People and Adults to Learn About the Medicine Ritlecitinib for Treatment of Patchy Hair Loss, Known by the Medical Term as Moderate Alopecia Areata

NCT07733765Alopecia Areata

DrugRitlecitinib

Pfizer

Phase 3

336

California, Florida, Illinois, Indiana, Iowa, Maryland, Michigan, North Carolina

2026-07-30

Recruiting

Extension Trial to Evaluate the Long-term Efficacy, Safety, and Tolerability of Maridebart Cafraglutide (MARITIME-2-EXTENSION)

NCT07684144Obesity, Overweight, Diabetes Mellitus, Type 2

DrugMaridebart cafraglutide

Amgen

Phase 3

950

Arizona, California, Florida, Illinois, Iowa, Kansas, Louisiana, Maryland

2026-07-29

Recruiting

Evaluation of the Efficacy and Safety of Magnetic Resonance Angiography (MRA) Using Gadopiclenol Compared to Gadoterate Meglumine in the Assessment of Steno-occlusive Disease in Adult Patients With Suspected Vascular Disease

NCT07348640Steno-occlusive Disease

DrugsGadopiclenol·Gadoterate meglumine

Guerbet

Phase 3

315

Alabama, California, Colorado, Illinois, Minnesota, Washington

2026-07-28

Recruiting

A Study to Assess the Safety, Tolerability and How Single Ascending Doses of ABBV-859 Moves Through the Body of Healthy Adult Participants

NCT07736638Healthy Volunteer

AbbVie

Phase 1

California, Illinois

2026-07-28

Recruiting

Study of Olatorepatide in Adult Participants Living With Overweight or Obesity Without Diabetes

NCT07685808Overweight or Obesity

DrugOlatorepatide

Regeneron Pharmaceuticals

Phase 2

360

Alabama, California, Connecticut, Florida, Illinois, Kansas, Kentucky, Nebraska

2026-07-28

Recruiting

A Study to Test Whether Nerandomilast Helps People With Systemic Sclerosis

NCT07497087Systemic Sclerosis

Boehringer Ingelheim

Phase 3

448

Alabama, Arizona, California, Colorado, District of Columbia, Florida, Illinois, Louisiana

2026-07-27

Recruiting

Extension Trial to Evaluate the Long-term Efficacy, Safety, and Tolerability of Maridebart Cafraglutide (MARITIME-1-EXTENSION)

NCT07684235Obesity, Overweight

DrugMaridebart cafraglutide

Amgen

Phase 3

3,200

Alabama, California, Connecticut, Florida, Georgia, Hawaii, Idaho, Illinois

2026-07-23

Recruiting

A Study of Esketamine Nasal Spray Versus Placebo Spray in Adult Participants With Treatment-resistant Depression

NCT07716098Depressive Disorder, Treatment-Resistant

DrugEsketamine

Janssen Research & Development, LLC

Phase 3

348

California, Georgia, Illinois, New York, Washington

2026-07-23

Recruiting

Vorasidenib Study in Pediatric Participants With Grade 2 Astrocytoma or Oligodendroglioma With an IDH1 or IDH2 Mutation

NCT07286292Grade 2 Astrocytoma or Oligodendroglioma With an IDH1 or IDH2 Mutation

DrugVorasidenib

Institut de Recherches Internationales Servier (I.R.I.S.)

Phase 2

California, Illinois, Massachusetts, Minnesota

2026-07-23

Recruiting

Phase 1/2 Study of Respiratory Syncytial Virus and Human Metapneumovirus (RSV+HMPV) Vaccine Candidate in Adults 60 Years of Age and Older

NCT07734649Respiratory Syncytial Virus Immunization, Human Metapneumovirus Immunization, Healthy Volunteers

DrugHMPV vaccine

Sanofi

Phase 1/2

2,400

Alabama, California, District of Columbia, Florida, Georgia, Illinois, Indiana, Louisiana

2026-07-22

Recruiting

A Phase 2 Study of VS-7375 in Patients With KRAS G12D-Mutated Non-Small Cell Lung Cancer

NCT07659782Non-Small Cell Lung Cancer

DrugVS-7375

Verastem, Inc.

Phase 2

105

Arizona, California, Florida, Georgia, Illinois, New Jersey, New York, North Carolina

2026-07-22

Recruiting

Safety and Efficacy of J147 in Acute Ischemic Stroke

NCT07430917Acute Ischemic Stroke

Abrexa Pharmaceuticals, Inc.

Phase 2

196

California, Illinois, New York, Oregon, Texas

2026-07-22

Recruiting

A US Study That Observes How Parkinson's Disease Changes Over Time in Patients Who Still Have Movement Symptoms Despite Taking Parkinson's Medications

NCT07330258Parkinson's Disease

Bayer

Observational

300

Arizona, California, Connecticut, Florida, Georgia, Illinois, Maryland, Massachusetts

2026-07-21

Recruiting

REGN15505 (PSMAx4-1BB) Alone or in Combination With Cemiplimab or REGN4336 (PSMAxCD3) in Adult Patients With Metastatic Castration-Resistant Prostate Cancer and Clear Cell Renal Cell Carcinoma

NCT07594106Metastatic Castration-Resistant Prostate Cancer (mCRPC), Clear Cell Renal Cell Carcinoma (ccRCC)

DrugsREGN4336·Cemiplimab

Regeneron Pharmaceuticals

Phase 1/2

265

Arizona, California, Florida, Illinois, Missouri, Texas

2026-07-20

Recruiting

A Clinical Study to Evaluate the Efficacy and Safety of Frevecitinib (KN-002) in Patients With Severe Asthma

NCT07532265Severe Asthma

Kinaset Therapeutics Inc

Phase 2

512

California, Florida, Illinois, Missouri, North Carolina, Pennsylvania, South Carolina, Texas

2026-07-16

Recruiting

Two Arm, Double-blind, Phase III Study Assessing Efficacy and Safety of Ianalumab Versus Placebo, in Participants With Sjögren's Disease With High Symptom Burden

NCT07621809Sjögren´s Disease

DrugIanalumab

Novartis Pharmaceuticals

Phase 3

570

Arizona, Florida, Illinois, Massachusetts, Michigan, New Jersey, New York, North Carolina

2026-07-16

Recruiting

An Open-label Study to Investigate the Efficacy and Safety of Dato-DXd + Rilvegostomig vs SoC in Adult Participants With High-risk MIUC

NCT07720284High-risk Muscle Invasive Urothelial Carcinoma

DrugsRilvegostomig·Enfortumab Vedotin·Dato-DXd·Opdivo

AstraZeneca

Phase 3

915

Arkansas, California, Illinois, Massachusetts, Missouri, Nebraska, New York, Ohio

2026-07-16

Active, closed

Study to Assess How Different Oral Formulations of Ubrogepant Move Through the Body in Healthy Adult Participants

NCT07680686Healthy Volunteer

DrugUbrogepant

AbbVie

Phase 1

Illinois

2026-07-14

Recruiting

Efficacy and Safety of Aleniglipron in Participants With Obesity or Overweight With a Weight-Related Comorbidity (ACCOMPLISH-1)

NCT07654361Obesity, Overweight, Chronic Weight Management

DrugAleniglipron

Gasherbrum Bio, Inc., a wholly owned subsidiary of Structure Therapeutics

Phase 3

3,600

Alabama, Arizona, California, Florida, Georgia, Hawaii, Idaho, Illinois

2026-07-13

Recruiting

DAREON®-NEC-1: A Study in People With Advanced Extrapulmonary Neuroendocrine Cancer (epNEC) to Compare Obrixtamig Plus Carboplatin and Etoposide Treatment With Standard Chemotherapy

NCT07544654Extrapulmonary Neuroendocrine Cancer (epNEC)

DrugsObrixtamig·Etoposide·Carboplatin

Boehringer Ingelheim

Phase 3

390

Arizona, California, Florida, Georgia, Illinois, Maryland, Massachusetts, Minnesota

2026-07-10

Recruiting

An Extension Study to Assess Safety and Efficacy of Remibrutinib in Participants With Moderate to Severe HS

NCT07665437Hidradenitis Suppurativa

DrugRemibrutinib

Novartis Pharmaceuticals

Phase 3

710

Alabama, Arkansas, California, Florida, Illinois, Indiana, Nebraska, New York

2026-07-10

Recruiting

Consumer Evaluation of an Investigational Intermittent Catheter

NCT07714694Urinary Retention, Neurogenic Bladder

Hollister Incorporated

Not applicable

Illinois

2026-07-09

Active, closed

A Study to Characterize the Safety and Immunogenicity of AZD6489 in Participants 60 Years of Age and Older (ARIES)

NCT07717840RSV Respiratory Syncytial Virus

AstraZeneca

Phase 1/2

164

California, Illinois, Kansas, Missouri, Nebraska

2026-07-08

Recruiting

Intalight Reference Database Protocol for VG200D

NCT07751484The Focus of This Study is to Collect OCT Data on Normal Eyes

Intalight, Inc

Observational

350

California, Illinois, Indiana

2026-07-08

Recruiting

Retinal Fundus Imaging and OCT Imaging for Ocular Detection of ATTR-CM

NCT07690436Transthyretin Amyloid Cardiomyopathy

AstraZeneca

Observational

500

California, Florida, Illinois, Massachusetts, Oregon, Tennessee

2026-07-08

Recruiting

A Phase III Study to Investigate the Efficacy and Safety of Elecoglipron Compared With Placebo in Adults With Type 2 Diabetes Mellitus and Impaired Renal Function on Background Dapagliflozin

NCT07662135Type 2 Diabetes Mellitus, Type 2 Diabetes With Chronic Kidney Disease

DrugElecoglipron

AstraZeneca

Phase 3

900

Arizona, California, Florida, Illinois, Massachusetts, Michigan, Minnesota, Missouri

2026-07-06

Recruiting

A Phase III Study to Investigate the Efficacy and Safety of the Combination of Elecoglipron and Dapagliflozin in Adults With Type 2 Diabetes Mellitus

NCT07662109Type 2 Diabetes Mellitus

DrugsElecoglipron·Dapagliflozin

AstraZeneca

Phase 3

2,000

Alabama, Arkansas, California, Florida, Georgia, Illinois, Indiana, Iowa

2026-07-06

Recruiting

A Study to Find Out if the Study Drug Elecoglipron Helps Adults With Type 2 Diabetes Mellitus by Comparing it With Semaglutide, a Medicine Already Used to Treat Type 2 Diabetes Mellitus

NCT07662213Type 2 Diabetes Mellitus

DrugsElecoglipron·Semaglutide

AstraZeneca

Phase 3

1,200

Alabama, Arizona, California, Connecticut, Florida, Georgia, Idaho, Illinois

2026-07-06

Recruiting

A Post-Market Assessment of the Safety and Performance of the TriClip™ System

NCT07586995Tricuspid Regurgitation (TR)

Abbott Medical Devices

Observational

1,000

Arizona, California, Illinois, Texas, Virginia

2026-07-02

Recruiting

Symbiotic-Lung-14: A Study to Learn About the Study Medicine Called PF08634404 in Combination With Chemotherapy in Adult Participants With Transformed Small Cell Lung Cancer

NCT07476287Small Cell Lung Cancer, Small Cell Lung Cancer ( SCLC ), Transformed Small Cell Lung Cancer, Lung Neoplasms

DrugPF-08634404

Pfizer

Phase 2

California, Illinois, New Jersey, New York

2026-07-02

Recruiting

A Study to Evaluate Adverse Events and Change in Disease Activity of Intravenous ABBV-706 Versus Standard of Care in Adult Participants With Relapsed/Refractory Small Cell Lung Cancer

NCT07365241Small Cell Lung Cancer

DrugsABBV-706·Amrubicin·Lurbinectedin·Topotecan

AbbVie

Phase 3

531

Alabama, Arizona, California, Florida, Georgia, Illinois, Indiana, Kentucky

2026-07-02

Recruiting

Parasternal Extravascular ICD System Pivotal Clinical Investigation (ALARION EV) Study

NCT07324031Ventricular Arrythmia, Ventricular Fibrillation, Ventricular Tachycardia

AtaCor Medical, Inc.

Not applicable

280

Arizona, Arkansas, California, District of Columbia, Florida, Georgia, Illinois, Kentucky

2026-07-02

Recruiting

Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Crinecerfont in Participants With Classic Congenital Adrenal Hyperplasia (CAH) Who Are Less Than 4 Years Old

NCT07536269Congenital Adrenal Hyperplasia

DrugCrinecerfont

Neurocrine Switzerland GmbH

Phase 2

California, Colorado, Connecticut, Georgia, Illinois, Indiana, Michigan, Minnesota

2026-07-01

Recruiting

Efficacy and Safety of Intranasal Cenegermin in Adult Participants With Non-Arteritic Anterior Ischemic Optic Neuropathy (NAION)

NCT07453888Non-Arteritic Anterior Ischemic Optic Neuropathy

DrugCenegermin

Dompé Farmaceutici S.p.A

Phase 3

272

California, Colorado, Florida, Georgia, Illinois, Kentucky, Maryland, Massachusetts

2026-07-01

Recruiting

Pridopidine Phase 3 Study in Huntington's Disease

NCT07609108Huntington Disease

DrugPridopidine

Prilenia

Phase 3

400

Alabama, California, District of Columbia, Florida, Illinois, Kansas, Maryland, Massachusetts

2026-07-01

Recruiting

A Study to Evaluate the Efficacy and Safety of Elismetrep (K-304) in the Acute Treatment of Migraine

NCT07645924Migraine

DrugElismetrep

Kallyope Inc.

Phase 3

1,800

Alabama, Arizona, Arkansas, California, Colorado, Connecticut, Georgia, Illinois

2026-07-01

Not yet open

Post-market Clinical Investigation Plan: Collagen Dura Regeneration Membrane - Repair (DMR)

NCT07371091Repair of Dura Mater

Collagen Matrix

Observational

110

Illinois, Massachusetts

2026-07

Recruiting

A Multi-Site Study to Assess the Effect of Availability of a Heated Tobacco Product on Smoking Abstinence Among Current Primary Cigarette Smokers

NCT07710820Smoking, Tobacco

RAI Services Company

Not applicable

1,060

Florida, Illinois, Nevada, Texas

2026-07

Not yet open

Study of Shunt Flow Under Different Valve Settings Using a Wireless Sensor

NCT07679035Hydrocephalus

Rhaeos, Inc.

Not applicable

Illinois

2026-06-30

Recruiting

Symbiotic-Lung-10: A Study to Learn About PF-08634404 Alone or in Combination in Early-stage or Locally Advanced NSCLC

NCT07489066Carcinoma, Non-Small-Cell Lung, Lung Cancer (NSCLC), Lung Neoplasms

DrugPF-08634404

Pfizer

Phase 2

120

Alabama, California, Georgia, Illinois, Nebraska, New Mexico, Tennessee

2026-06-30

Recruiting

A Phase 3 Study of Rezpegaldesleukin (NKTR-358) for Patients ≥ 12 Years of Age With Moderate-to-Severe Atopic Dermatitis

NCT07690371Moderate-to-Severe Atopic Dermatitis

DrugRezpegaldesleukin

Nektar Therapeutics

Phase 3

510

Arizona, Arkansas, California, Florida, Georgia, Idaho, Illinois, Kentucky

2026-06-29

Recruiting

Study to Determine if BHV-1300 is Effective and Safe in Adults With Graves' Disease

NCT07661056Graves Disease

DrugBHV-1300

Biohaven Therapeutics Ltd.

Phase 3

300

Arizona, California, District of Columbia, Florida, Georgia, Illinois, Kansas, Louisiana

2026-06-26

Recruiting

Study of AZD0120 in Newly Diagnosed Multiple Myeloma Ineligible for ASCT

NCT07764978Newly Diagnosed Multiple Myeloma

DrugsAZD0120·Isatuximab·Bortezomib·Daratumumab

AstraZeneca

Phase 3

750

Arizona, California, Colorado, Connecticut, Florida, Georgia, Illinois, Iowa

2026-06-26

Recruiting

A Chronic Pain Master Protocol (CPMP): A Study of LY4065967 in Participants With Osteoarthritis Pain

NCT07641517Osteoarthritis, Knee, Chronic Pain

DrugLY4065967

Eli Lilly and Company

Phase 2

150

Alabama, Arizona, California, Connecticut, Florida, Georgia, Illinois, Louisiana

2026-06-25

Recruiting

A Study to Evaluate TNX-102 SL Monotherapy Versus Placebo in Participants With Major Depressive Disorder (MDD)

NCT07621237Major Depressive Episode (MDE), Major Depressive Disorder (MDD), Depression

DrugCyclobenzaprine

Tonix Pharmaceuticals, Inc.

Phase 2

360

Arizona, California, Florida, Georgia, Illinois, Louisiana, Maryland, Massachusetts

2026-06-25

Recruiting

An Open-label, Single-arm Study of Prophylaxis for Datopotamab Deruxtecan (Dato-DXd) -Related Stomatitis in Eligible Patients With Metastatic or Inoperable Locally Recurrent Breast Cancer or Locally Advanced or Metastatic Epidermal Growth Factor Receptor-Mutated Non-small Cell Lung Cancer.

NCT07357597Stomatitis

DrugDato-DXd

AstraZeneca

Phase 4

100

Arizona, Arkansas, California, District of Columbia, Florida, Georgia, Idaho, Illinois

2026-06-24

Recruiting

A Study to Assess Safety, Tolerability, and How Single and Multiple Injections or Infusions of ABBV-313 Affects the Body of Adult Participants

NCT07673120Healthy Volunteers

AbbVie

Phase 1

California, Illinois

2026-06-24

Active, closed

A Study to Evaluate How Multiple Doses of Itraconazole Interacts With Nacresertib in Healthy Adult Participants

NCT07649954Healthy Volunteer

DrugItraconazole

AbbVie

Phase 1

Illinois

2026-06-23

Recruiting

KQB198 in Combination With Imatinib in Participants With Advanced/Metastatic GIST in 1st Line Setting (SynerGIST-1st Line)

NCT07406633GIST - Gastrointestinal Stromal Tumor, GIST, GIST Metastatic Cancer, Gastro Intestinal Stromal Tumour

DrugsKQB198·Imatinib

Kumquat Biosciences Inc.

Phase 2

California, Florida, Illinois, Iowa, Massachusetts, Michigan, Minnesota, New York

2026-06-23

Recruiting

A Study of MZE782 in Adults With PKU

NCT07694440Phenylketonuria (PKU)

Maze Therapeutics

Phase 2

California, Illinois, Indiana, Kentucky, Pennsylvania, Tennessee

2026-06-23

Recruiting

BEACON - Phase III Clinical Study of Rugonersen in Angelman Syndrome.

NCT07605429Angelman Syndrome

OHB Pediatrics Ltd.

Phase 3

165

California, Florida, Illinois, North Carolina

2026-06-23

Recruiting

Study of Efficacy and Safety of Tonlamarsen in Participants With a Recent Hospitalization and a Concurrent Episode of Acute Severe Hypertension

NCT07511361Hypertension, Acute Severe Hypertension, Hypertensive Emergency, Hypertensive Urgency

Kardigan, Inc.

Phase 2

140

Colorado, Florida, Illinois, Michigan, New York, Ohio, South Carolina, Tennessee

2026-06-23

Recruiting

Study of the Shockwave Medical SkyRunner Carotid Intravascular Lithotripsy (IVL) System for the Treatment of Calcified Carotid Arteries Prior to Trans-Carotid Stenting (SKYWARD Trans-Carotid IDE [Investigational Device Exemption] Study)

NCT07062471Carotid Artery Calcification, Carotid Artery Diseases

Shockwave Medical, Inc.

Not applicable

185

Arkansas, California, District of Columbia, Florida, Illinois, Massachusetts, Michigan, Minnesota

2026-06-22

Active, closed

A Study of T-Cell Receptor Engineered Donor T Cells in Subjects Undergoing Allogeneic Peripheral Blood Stem Cell Transplantation

NCT07702578AML, MDS

DrugTSC-101

TScan Therapeutics, Inc.

Phase 3

310

Arizona, California, Colorado, Connecticut, Florida, Georgia, Illinois, Kansas

2026-06-18

Recruiting

A Study to Investigate the Safety, Tolerability, and Pharmacokinetics of RO7663498 Following Intravitreal Administration in Participants With Diabetic Retinopathy

NCT07588100Diabetic Retinopathy

Hoffmann-La Roche

Phase 1

California, Illinois, Ohio, Texas

2026-06-18

Recruiting

A Clinical Trial of Calderasib (MK-1084) and Durvalumab in People With Non-Small Cell Lung Cancer (MK-1084-015/KANDLELIT-015)

NCT07554339Non-small Cell Lung Cancer

DrugsCalderasib·Durvalumab

Merck Sharp & Dohme LLC

Phase 3

310

Illinois, Nebraska, New York, North Carolina, Virginia

2026-06-18

Recruiting

xDot Access Management System Early Feasibility Study

NCT07464353Vascular Closure Devices

xDot Medical, Inc

Not applicable

Illinois, Minnesota, Oklahoma, South Dakota, Wisconsin

2026-06-16

Recruiting

A Phase 2 Study of VS-7375 in Patients With KRAS G12D-Mutated Pancreatic Cancer

NCT07644559Pancreatic Ductal Adenocarcinoma (PDAC), G12D Mutated KRAS

DrugsVS-7375·Cetuximab

Verastem, Inc.

Phase 2

185

California, Florida, Illinois, Maryland, Massachusetts, Michigan, Minnesota, Missouri

2026-06-16

Not yet open

NaviCam Patency Capsule to Verify Gastrointestinal Patency

NCT07649720Intestinal Stricture, Crohn Disease, NSAID (Non-Steroidal Anti-Inflammatory Drug) Induced Enteropathy, Abdominal Pain

AnX Robotica Corp.

Not applicable

Illinois

2026-06-15

Recruiting

A Phase IIIb Study to Evaluate Camizestrant Plus Ribociclib in ER-positive, HER2-negative Advanced Breast Cancer

NCT07647328ER-Positive HER2-Negative Breast Cancer

DrugsCamizestrant·Ribociclib

AstraZeneca

Phase 3

150

California, Georgia, Illinois, Kentucky, Nevada, South Dakota, Tennessee, Texas

2026-06-15

Recruiting

Cantharidin Application in Patients With Common Warts (Verruca Vulgaris) (COVE-3)

NCT07637734Common Warts, Common Warts (Verruca Vulgaris), Human Papilloma Virus (HPV), Warts

Verrica Pharmaceuticals Inc.

Phase 3

300

California, Florida, Illinois, Kansas, Louisiana, Massachusetts, Minnesota, Nebraska

2026-06-15

Recruiting

A Safety and Efficacy Study of EIK1001 in Combination With Pembrolizumab and Chemotherapy in Participants With Stage 4 Non-Small Cell Lung Cancer.

NCT07365319Non Small Cell Lung Cancer (Squamous or Non Squamous), Stage 4 NSCLC

DrugsEIK1001·Cisplatin/Carboplatin·Nab-paclitaxel·Pemetrexed

Eikon Therapeutics

Phase 2/3

750

Alabama, California, Colorado, Florida, Illinois, New Mexico, New York, Tennessee

2026-06-15

Recruiting

A Study to Assess Real-World Use and Outcomes of TAR-200 for Participants With Non-Muscle Invasive Bladder Cancer (NMIBC) in the United States

NCT07309445Non-Muscle Invasive Bladder Neoplasms

Janssen Research & Development, LLC

Observational

150

Alabama, Arkansas, California, Colorado, Florida, Illinois, Indiana, Michigan

2026-06-12

Active, closed

A Study to Evaluate the Efficacy and Safety of Concomitant Use of Eplontersen and ALXN2220 Compared With Eplontersen and Placebo for Adults Participants With ATTR-CM

NCT07608354Transthyretin Amyloid Cardiomyopathy (ATTR-CM)

DrugsCliramitug·Eplontersen

AstraZeneca

Phase 2

326

California, Colorado, District of Columbia, Florida, Illinois, Massachusetts, Missouri, New York

2026-06-11

Recruiting

A Phase IIb Study to Evaluate AZD8965 in Participants With IPF.

NCT07652658Idiopathic Pulmonary Fibrosis (IPF)

AstraZeneca

Phase 2

359

Alabama, Arizona, California, Colorado, Florida, Georgia, Idaho, Illinois

2026-06-11

Recruiting

A Study to Learn About the Study Medicine Called Berobenatide (PF-08653944) in People With Overweight or Obesity

NCT07595549Obesity, Overweight and/or Obesity, Overweight

DrugBerobenatide

Pfizer

Phase 3

954

California, Florida, Illinois, Indiana, Kentucky, Maryland, Michigan, Nebraska

2026-06-10

Active, closed

A Research Study Comparing Different Ways of Increasing the Dose of NNC0662-0419 in Participants With Obesity

NCT07639021Obesity

DrugsNNC0662-0419·Semaglutide

Novo Nordisk A/S

Phase 2

233

Alabama, California, Florida, Illinois, Indiana, Kentucky, Maryland, Missouri

2026-06-09

Recruiting

Efficacy and Safety Study of TPX-115 on Partial-thickness Rotator Cuff Tear

NCT07219654Partial Thickness Rotator Cuff Tears

DrugTPX-115

Tego Science, Inc.

Phase 2

California, Florida, Illinois

2026-06-09

Recruiting

Study of GB-4362 With Enfortumab Vedotin and Pembrolizumab for Advanced Urothelial Cancer

NCT07484022Advanced Urothelial Cancer, Metastatic Urothelial Carcinoma

DrugsEnfortumab Vedotin·Pembrolizumab

Generate Biomedicines

Phase 1

California, Florida, Georgia, Illinois, New Jersey, New York, Texas, Virginia

2026-06-08

Recruiting

Atebimetinib + GnP as a First Line Treatment in Patients With Metastatic Pancreatic Adenocarcinoma

NCT07562152Pancreatic Cancer, Pancreatic Cancer Metastatic, PDAC, PDAC - Pancreatic Ductal Adenocarcinoma

Immuneering Corporation

Phase 3

510

Alabama, Arizona, California, Colorado, Delaware, Florida, Georgia, Illinois

2026-06-05

By invitation

Long-term Safety and Efficacy Evaluation of IMG-007 in Participants With Moderate-to-Severe Atopic Dermatitis

NCT07734415Atopic Dermatitis, Atopic Dermatitis Eczema, Eczema

DrugIMG-007

Inmagene LLC

Phase 2

400

California, Florida, Illinois, New York, North Carolina, North Dakota, Ohio, Oregon

2026-06-05

Recruiting

A Study of Lirafugratinib in Non-CCA Solid Tumors With FGFR2 Fusion or Rearrangement

NCT07359820FGFR2 Gene Fusion/Rearrangement, Other Solid Tumors, Adult

Elevar Therapeutics

Phase 2

Arizona, Florida, Illinois, Massachusetts, Minnesota, New York, Texas

2026-06-04

Recruiting

A Phase 3 Efficacy and Safety Study of HBS-301 in Participants With Narcolepsy

NCT07675135EDS, Cataplexy, Fatigue, Narcolepsy

DrugPitolisant

Harmony Biosciences Management, Inc.

Phase 3

258

Alabama, Arizona, California, Colorado, Florida, Georgia, Illinois, Indiana

2026-06-04

Recruiting

Food and Metabolism Study

NCT07624500Prediabetes, Insulin Resistance, Triglycerides, Lipids Metabolism

Clinical Nutrition Research Center, Illinois Institute of Technology

Not applicable

Illinois

2026-06-03

Recruiting

Ixoberogene Soroparvovec (Ixo-vec) Contralateral Dosing Study in Participants With Neovascular Age-related Macular Degeneration

NCT07630649Neovascular Age-Related Macular Degeneration (nAMD) Wet AMD

Adverum Biotechnologies, Inc.

Phase 2

Arizona, California, Florida, Hawaii, Illinois, New Jersey, South Carolina, Texas

2026-06-02

Recruiting

Surabgene Lomparvovec Administered in the Suprachoroidal Space in Adult Participants With Diabetic Retinopathy Without Center-Involved Diabetic Macular Edema

NCT07592273Diabetic Retinopathy

DrugSurabgene Lomparvovec

AbbVie

Phase 2/3

576

Arizona, California, Colorado, Florida, Georgia, Illinois, Kansas, Maine

2026-06-01

By invitation

Shortwave Infrared Surgical Imaging Device Study

NCT07744425Cholecystitis, Cholecystitis, Chronic, Chronic Calculous Cholecystitis, Primary Hyperparathyroidism

Cision Vision, Inc.

Observational

California, Illinois, Maryland

2026-05-29

Recruiting

A Study to Learn About How a New Pneumococcal Vaccine Works in Infants.

NCT07629440Pneumococcal Disease

DrugsPG4·Prevnar 20

Pfizer

Phase 3

3,230

Alabama, Arkansas, California, Colorado, Florida, Georgia, Idaho, Illinois

2026-05-29

Recruiting

A Study to Evaluate the Pharmacodynamics of a Combination of QCZ484 and Inclisiran in Participants With Hypertension and Concomitant Hypercholesterolemia

NCT07610278Hypercholesterolaemia

DrugsQCZ484·Inclisiran

Novartis Pharmaceuticals

Phase 2

120

Alabama, California, Florida, Georgia, Illinois, Kansas, Louisiana, Maryland

2026-05-29

Recruiting

Immune Modulation During Palynziq® Treatment in Adults (IMPALA)

NCT07477691Phenylketonuria

DrugsPegvaliase·Methotrexate

BioMarin Pharmaceutical

Phase 4

California, Colorado, Florida, Illinois, Indiana, Minnesota, New York, Oregon

2026-05-29

Recruiting

A Study of LY4152199 in Participants With Previously Treated B-cell Malignancies (BAF_FRontier-1 )

NCT07101328Lymphoma, Non-Hodgkin, B-cell Lymphoma, Lymphoma, Large B-Cell, Diffuse, Lymphoma, Follicular

Eli Lilly and Company

Phase 1

215

California, Colorado, Connecticut, Illinois, Iowa, Kansas, Massachusetts, Michigan

2026-05-28

Recruiting

A Study to Assess Adverse Events, How the Drug Moves Through the Body and Effectiveness of Intravenous Infusions and Subcutaneous Injections of ABBV-519 in Adult Participants With Systemic Lupus Erythematosus (SLE) or Rheumatoid Arthritis (RA)

NCT07607964Systemic Lupus Erythematosus, Rheumatoid Arthritis

AbbVie

Phase 1

Alabama, California, Florida, Illinois, Tennessee, Texas

2026-05-28

Recruiting

A Study to Learn About the Safety of Taking an Additional Dose of the Medicine Rimegepant in Adults With Migraine

NCT07609914Acute Treatment of Migraine

DrugRimegepant

Pfizer

Phase 4

400

California, Florida, Illinois, Indiana, Massachusetts, Michigan, Minnesota, Mississippi

2026-05-28

Recruiting

A Study to Evaluate the Efficacy and Safety of Rozanolixizumab in Adult Participants With Ocular Myasthenia Gravis

NCT07463521Ocular Myasthenia Gravis

DrugRozanolixizumab

UCB Biopharma SRL

Phase 3

120

Arizona, Illinois, New York, Ohio, Wisconsin

2026-05-27

Recruiting

A Phase 3 Study of Pelabresib (DAK539) and Ruxolitinib in Myelofibrosis (MF)

NCT07357727Primary Myelofibrosis (PMF), Post-polycythemia Vera Myelofibrosis (PPV-MF), Post-essential Thrombocythemia Myelofibrosis (PET-MF)

DrugsPelabresib·Ruxolitinib

Novartis Pharmaceuticals

Phase 3

460

Connecticut, Florida, Georgia, Illinois, Indiana, Maryland, New Jersey, New York

2026-05-27

Recruiting

A Study to Evaluate Efficacy, Safety, and Immunogenicity With ABP 938 8 mg Versus EYLEA® HD (Aflibercept) in Participants With Neovascular Age-related Macular Degeneration

NCT07614776Neovascular Age-related Macular Degeneration, nAMD

Amgen

Phase 3

304

California, Colorado, Connecticut, Florida, Illinois, Indiana, Maryland, Massachusetts

2026-05-27

Recruiting

A Study to Access Intravenous (IV) Telisotuzumab Adizutecan in Combination With IV Bevacizumab Compared to Standard of Care IV Bevacizumabin Combination With Oral Trifluridine and Tipiracil in Adult Participants With Refractory Metastatic Colorectal Cancer

NCT07525206Colorectal Cancer

DrugsTelisotuzumab Adizutecan·Trifluridine/Tipiracil·Bevacizumab

AbbVie

Phase 3

990

Arizona, Arkansas, California, Colorado, Connecticut, Florida, Georgia, Illinois

2026-05-22

Recruiting

Study of Zoldonrasib + Chemo of Investigator's Choice vs Placebo + Chemo of Investigator's Choice as First-line Treatment in Metastatic KRAS G12D-mutated Pancreatic Adenocarcinoma ( RASolute 305 )

NCT07621718Pancreatic Cancer, Pancreatic Cancer Metastatic, PDAC, PDAC - Pancreatic Ductal Adenocarcinoma

DrugsZoldonrasib·Leucovorin·Irinotecan·Adrucil

Revolution Medicines, Inc.

Phase 3

670

Arizona, Connecticut, Florida, Georgia, Illinois, Maryland, Massachusetts, Minnesota

2026-05-22

Recruiting

Study Evaluating the Efficacy of KITE-753 Versus Axicabtagene Ciloleucel in Participants With Relapsed or Refractory Large B-Cell Lymphoma After First-Line Therapy

NCT07479797Relapsed or Refractory Large B-cell Lymphoma

DrugsKITE-753·Axicabtagene Ciloleucel·Fludarabine·Cyclophosphamide

Kite, A Gilead Company

Phase 3

550

Arizona, California, Colorado, Connecticut, Florida, Georgia, Illinois, Maryland

2026-05-22

Recruiting

A Study of Donanemab (LY3002813) in Participants Who Completed Study AACM (TRAILBLAZER-ALZ 3-EXT).

NCT07602582Alzheimer Disease, Dementia, Plaque, Amyloid

DrugDonanemab

Eli Lilly and Company

Phase 3

550

Arizona, California, Florida, Georgia, Idaho, Illinois, Indiana, Iowa

2026-05-22

Recruiting

A Study to Compare Elritercept With Epoetin Alfa to Treat Anemia in Adults With Very Low, Low, or Intermediate Risk Myelodysplastic Syndromes (MDS) Who Need Regular Blood Transfusions

NCT07422480Myelodysplastic Syndrome, Anemia

DrugsElritercept·Epoetin Alfa

Takeda

Phase 3

300

Arizona, California, Connecticut, Florida, Georgia, Illinois, Kentucky, Louisiana

2026-05-21

Recruiting

A Study of Zanzalintinib in Participants With Recurrent or Progressive Meningioma

NCT07428616Meningioma

DrugZanzalintinib

Exelixis

Phase 2

100

Alabama, Arizona, California, Florida, Illinois, Louisiana, Massachusetts, Missouri

2026-05-21

Recruiting

A Study of Zunveyl on Safety, Tolerability, Neuropsychiatric Symptoms, and Caregiver Distress in Alzheimer's Disease (RESOLVE)

NCT07633470Alzheimer Disease

Alpha Cognition, Inc

Phase 4

150

California, Florida, Georgia, Illinois, Indiana, Massachusetts, Michigan, Missouri

2026-05-20

Recruiting

Mathematical Modeling of Blood Sugar and Hormone Responses in Insulin-Dependent Type 2 Diabetes

NCT07650682Type 2 Diabetes, Insulin Dependent Diabetes

Clinical Nutrition Research Center, Illinois Institute of Technology

Observational

Illinois

2026-05-20

Recruiting

Evaluation of Gixam's Efficacy Predicting the Presence of Advanced and Non-advanced Colorectal Neoplasia in a FIT Negative Population

NCT07623902CRC Screening, Microbiome

Jubaan Ltd.

Not applicable

1,436

Alabama, California, Florida, Illinois, New York, Ohio, Virginia

2026-05-18

Recruiting

A Study to Investigate Weight Management With Macupatide and Eloralintide, Alone or in Combination, in Adult Participants With Obesity or Overweight

NCT07589608Overweight, Obesity

DrugsMacupatide·Eloralintide

Eli Lilly and Company

Phase 2

400

Arizona, California, Connecticut, Florida, Idaho, Illinois, Kansas, Kentucky

2026-05-15

Recruiting

A Study to Evaluate the Effectiveness of DT-101 as an Adjunctive Treatment in Patients With Depression

NCT07610473Major Depressive Disorder (MDD)

DrugDT-101

Draig Therapeutics Ltd

Phase 2

118

Arizona, Arkansas, California, Florida, Georgia, Illinois, Massachusetts, New York

2026-05-14

Recruiting

Symbiotic-GI-16: A Study to Learn About the Study Medicine Called PF-08634404 in Combination With Chemotherapy in Gastroesophageal Cancer

NCT07392892Untreated Advanced or Metastatic Gastric, Gastroesophageal Junction , or Esophageal Adenocarcinoma, Metastatic Gastric Cancer, Gastroesophageal Junction Cancer, Esophageal Adenocarcinoma

DrugsPF-08634404·Nivolumab

Pfizer

Phase 2/3

840

California, Colorado, Florida, Illinois, Maryland, Nevada, New Jersey, New York

2026-05-14

Recruiting

A Study to Assess How Well and Safely Elafibranor Works in Adult Participants With Primary Sclerosing Cholangitis

NCT07387549Primary Sclerosing Cholangitis

DrugElafibranor

Ipsen

Phase 3

350

Arizona, California, Colorado, Connecticut, District of Columbia, Florida, Georgia, Illinois

2026-05-14

Recruiting

AtraUmatic Laparoscopic HerNia Repair Clinical Investigation to Evaluate the Safety and Performance of The ECLIPSIUM System for Mesh Fixation IDE

NCT07277946Hernia

Tissium

Not applicable

240

California, Florida, Illinois, Kentucky, Michigan, Nebraska, North Carolina, Ohio

2026-05-14

Recruiting

Efficacy of the Omnipod® 6 System Compared With the Omnipod® 5 System

NCT07579702Type 2 Diabetes Mellitus, Type 1 Diabetes Mellitus

Insulet Corporation

Not applicable

200

California, Colorado, Connecticut, Georgia, Illinois, Indiana, Massachusetts, Michigan

2026-05-13

Recruiting

A Phase 2 Study to Evaluate Povetacicept in Adults With Generalized Myasthenia Gravis

NCT07501702Myasthenia Gravis, Generalized

DrugPovetacicept

Vertex Pharmaceuticals Incorporated

Phase 2

California, Florida, Hawaii, Illinois, Nevada, South Carolina, Tennessee, Texas

2026-05-13

Recruiting

Study of NMS-03305293 in Adult Patients With Relapsed Ovarian Cancer

NCT06930755Ovarian Cancer

DrugsNMS-03305293·Topotecan

Nerviano Medical Sciences

Phase 1

Illinois, Missouri, Pennsylvania, Tennessee, Texas

2026-05-13

Recruiting

An Evaluation of Long-Term Supplement Use on Biological Age and Metabolic Health Markers - The BioAge Trial

NCT07755943Generally Healthy Adults Who Are Long-term Supplement Users

Shaklee Corporation

Observational

300

Illinois

2026-05-12

Recruiting

Sarilumab Efficacy and Safety in Adults With Early Polymyalgia Rheumatica

NCT07286214Polymyalgia Rheumatica

DrugSarilumab

Sanofi

Phase 4

300

Arizona, California, Colorado, Florida, Georgia, Illinois, Maryland, Missouri

2026-05-12

Recruiting

Pivotal Study of the SUpira System in Patients Undergoing High-Risk Percutaneous COronaRy InTervention (HRPCI)

NCT07296744Coronary Artery Disease, High Risk Percutaneous Coronary Intervention, Interventional Cardiology, Mechanical Circulatory Support

Supira Medical

Not applicable

358

California, Georgia, Illinois, Michigan, Minnesota, Missouri, New Jersey, New York

2026-05-11

Recruiting

Efficacy, Safety and Tolerability of Switching From Glucagon-like Peptide-1 Receptor Agonists (GLP-1RA) to Maridebart Cafraglutide in Adults With Obesity or Overweight (MARITIME-SWITCH)

NCT07575399Obesity or Overweight

DrugMaridebart cafraglutide

Amgen

Phase 3

300

Alabama, Arizona, California, Florida, Georgia, Hawaii, Idaho, Illinois

2026-05-11

Recruiting

Enfortumab Vedotin in Combination With Pembrolizumab vs. Concurrent Chemoradiotherapy (cCRT) in People With Muscle Invasive Bladder Cancer (EV-309)

NCT07566156Urothelial Cancer, Urinary Bladder Neoplasms

DrugsMitomycin C·Enfortumab Vedotin·Fluorouracil·Keytruda

Astellas Pharma Global Development, Inc.

Phase 3

390

California, Colorado, Delaware, Illinois, Indiana, Missouri, Ohio, Oregon

2026-05-11

Active, closed

A Study of PF-08653945 and PF-08653944 in Adults With Overweight or Obesity

NCT07575932Overweight, Obesity, Overweight and/or Obesity, Overweight or Obesity

DrugsPF-08653945·Berobenatide

Pfizer

Phase 2

940

Arizona, California, Florida, Georgia, Illinois, Kansas, Louisiana, Maryland

2026-05-11

Recruiting

A Study on the Immune Response and Safety of an Investigational Combined Measles, Mumps, Rubella and Varicella Vaccine, When Administered as Intramuscular Injection to Healthy Children 15 Months to 6 Years of Age

NCT07406360Measles, Measles-Mumps-Rubella+Chickenpox Vaccine

GlaxoSmithKline

Phase 3

1,209

Alabama, California, Florida, Georgia, Illinois, Michigan, Ohio, South Carolina

2026-05-11

Recruiting

A Study to Select a Dose Regimen (Part A) and to Investigate Overall Survival (Part B) With Nanvuranlat Compared With Physician's Best Choice in Participants Aged 18 Years or Older With Biliary Tract Cancer

NCT07265674Advanced Biliary Tract Cancer, Biliary Tract Cancer (BTC)

J-Pharma Co., Ltd.

Phase 3

480

California, Florida, Illinois, Kentucky, Louisiana, Michigan, Minnesota, Nevada

2026-05-11

Recruiting

A Phase 3 Trial of DT120 for Major Depressive Disorder (Ascend)

NCT07592689Major Depressive Disorder

DrugDT120

Definium Therapeutics US, Inc.

Phase 3

165

Arkansas, California, Colorado, Florida, Georgia, Illinois, Massachusetts, Missouri

2026-05-10

Recruiting

A Phase 2 Trial of Dotinurad in Xanthine Oxidase Inhibitor (XOI) Intolerant/Uricase Failure Gout Participants

NCT07535034Gout

DrugDotinurad

Crystalys Therapeutics

Phase 2

Alabama, Arizona, California, Colorado, Florida, Georgia, Illinois, Kentucky

2026-05-08

Active, closed

Safety and Preliminary Efficacy of TSHA-102 Gene Therapy in Pediatric Females Aged >2 to <4 Years With Rett Syndrome

NCT07480564Rett Syndrome

Taysha Gene Therapies, Inc.

Phase 3

Alabama, Illinois, Massachusetts

2026-05-08

Recruiting

Signatera-Guided CDK4/6 Inhibitor Therapy in Breast Cancer

NCT07214532Breast Neoplasms, Carcinoma, Ductal, Breast, Receptors, Estrogen (for ER-positive Requirement)

Natera, Inc.

Not applicable

725

Arizona, California, Colorado, Connecticut, Florida, Illinois, Indiana, Louisiana

2026-05-08

Recruiting

An Open-label Extension Safety and Efficacy Study of QCZ484 in Hypertensive Patients.

NCT07543120Hypertension (HTN)

DrugQCZ484

Novartis Pharmaceuticals

Phase 2

323

California, Florida, Georgia, Illinois, Kansas, Maryland, Michigan, Missouri

2026-05-07

Recruiting

A Phase 3 Randomized Clinical Trial to Investigate the Safety and Efficacy of Palopegteriparatide at Doses Greater Than 30 μg/Day in Adult Participants With Hypoparathyroidism

NCT07081997Hypoparathyroidism, Endocrine System Diseases, Parathyroid Diseases

Ascendis Pharma Bone Diseases A/S

Phase 3

Colorado, Illinois, Minnesota, Nevada, New York, North Carolina, Texas, Washington

2026-05-07

Recruiting

An Open-label, Rollover Trial to Evaluate the Efficacy and Safety of AMG 732 in Participants With Thyroid Eye Disease

NCT07438405Thyroid Eye Disease

DrugAMG 732

Amgen

Phase 2

Arkansas, Florida, Illinois, West Virginia

2026-05-07

Recruiting

A Study of Brenipatide (LY3537031) in Participants With Irritable Bowel Syndrome-Diarrhea (IBS-D)

NCT07545759Irritable Bowel Syndrome, Diarrhea

DrugBrenipatide

Eli Lilly and Company

Phase 2

531

Arizona, California, Florida, Illinois, Indiana, Kentucky, Michigan, Minnesota

2026-05-06

Recruiting

A Study of Precemtabart Tocentecan With or Without Bevacizumab Compared to Trifluridine/Tipiracil Plus Bevacizumab in Participants With Previously Treated Metastatic Colorectal Cancer (PROCEADE-CRC-03)

NCT07549412Metastatic Colorectal Cancer

DrugsTrifluridine/Tipiracil·Bevacizumab

EMD Serono Research & Development Institute, Inc.

Phase 3

1,020

Colorado, Florida, Illinois, Michigan, Minnesota, Missouri, New York, Tennessee

2026-05-06

Recruiting

A Study to Identify and Characterize Patients With Type 2 Diabetes Mellitus for Possible Participation in Ongoing or Future Type 2 Diabetes Mellitus Clinical Studies

NCT07606066Type 2 Diabetes

AstraZeneca

Observational

2,150

Arizona, Arkansas, California, Florida, Georgia, Illinois, Kansas, Maryland

2026-05-06

Recruiting

Surovatamig as Consolidation Therapy in Participants With Chronic Lymphocytic Leukaemia or Small Lymphocytic Lymphoma With Unmutated Immunoglobulin Heavy Chain Variable (IGHV)

NCT07509151Chronic Lymphocytic Leukaemia or Small Lymphocytic Lymphoma With Unmutated IGHV

DrugSurovatamig

AstraZeneca

Phase 3

420

California, Colorado, Connecticut, Illinois, Kansas, Kentucky, Maryland, Massachusetts

2026-05-05

Recruiting

AMAZE 4: A Research Study Investigating How Well the Medicine NNC0487-0111 Helps People With Excess Body Weight and Obstructive Sleep Apnoea Treated With Positive Airway Pressure Lose Weight and Improve Sleep Apnoea

NCT07571109Obesity, Overweight, Obstructive Sleep Apnoea

DrugNNC0487-0111

Novo Nordisk A/S

Phase 3

300

Arizona, Florida, Georgia, Illinois, New York, North Dakota, Ohio, Pennsylvania

2026-05-05

Recruiting

AMAZE 3: A Research Study Investigating How Well the Medicine NNC0487-0111 Helps People With Excess Body Weight and Obstructive Sleep Apnoea Not Treated With Positive Airway Pressure Lose Weight and Improve Sleep Apnoea

NCT07571005Obesity, Overweight, Obstructive Sleep Apnoea

DrugNNC0487-0111

Novo Nordisk A/S

Phase 3

300

California, Florida, Georgia, Illinois, New York, Ohio, Pennsylvania, Texas

2026-05-05

Recruiting

A Study to Learn About the Safety of an Expanded Pneumococcal Vaccine in Healthy Infants

NCT07573462Pneumococcal Disease

DrugsPG4·Prevnar 20

Pfizer

Phase 3

2,400

Florida, Georgia, Idaho, Illinois, Kentucky, Louisiana, Massachusetts, New York

2026-05-04

Recruiting

AZD2265 Compared With Standard of Care in PSMA-positive Metastatic Castration-resistant Prostate Cancer (VECTRA-01)

NCT07611110Metastatic Castration-resistant Prostate Cancer

DrugsXofigo·FPI-2265·Cabazitaxel·Zytiga

AstraZeneca

Phase 3

670

Alabama, Arizona, California, Colorado, Florida, Illinois, Louisiana, Michigan

2026-05-04

Recruiting

A Study of LY4395089 and Mirikizumab (LY3074828) Given Together and Mirikizumab (Alone) in Adults With Crohn's Disease

NCT07483099Crohn Disease

DrugsLY4395089·Mirikizumab

Eli Lilly and Company

Phase 2

Arizona, California, Colorado, Florida, Georgia, Illinois, Kansas, Michigan

2026-05-04

Recruiting

A Clinical Trial of Adjuvant Intismeran (V940) With or Without Pembrolizumab Coformulated With Berahyaluronidase Alfa (MK-3475A) in High-Risk Stage I Non-Small Cell Lung Cancer (V940-014)

NCT07513376Non-small Cell Lung Cancer

DrugsPembrolizumab Formulated with Berahyaluronidase Alfa·Intismeran autogene

Merck Sharp & Dohme LLC

Phase 3

876

California, Colorado, Connecticut, Florida, Illinois, Missouri, Montana, Nebraska

2026-05-04

Recruiting

A Master Protocol (IIBD): A Study of Multiple Drugs in Adults With Ulcerative Colitis or Crohn's Disease

NCT07483073Colitis, Ulcerative, Crohn Disease

DrugsLY4395089·Mirikizumab

Eli Lilly and Company

Phase 2

Arizona, California, Colorado, Florida, Georgia, Illinois, Kansas, Michigan

2026-05-04

Not yet open

Occlutech AFR Fontan Study

NCT07532369Failure of Fontan Type Circulation, Fenestration, Univentricular Heart, Congenital Anomaly

Occlutech International AB

Observational

Alabama, California, Colorado, Illinois, North Carolina, Texas

2026-05-01

Recruiting

Trial Comparing the Safety and Efficacy of Two Different Oral VPV Doses With Placebo as Treatment for RV in Participants With COPD

NCT07610395Rhinovirus Infection

Altesa Biosciences, Inc.

Phase 2

180

Alabama, Arizona, California, Florida, Georgia, Illinois, Indiana, Kentucky

2026-05-01

Recruiting

A Study to Evaluate the Pharmacokinetics, Safety, and Tolerability of Single Ascending Doses of ABBV-1451 Infusions and Injections in Healthy Adult Participants

NCT07570147Healthy Volunteer

AbbVie

Phase 1

Illinois

2026-05-01

Recruiting

Evaluation of the Fully Closed Loop Omnipod® System in Type 2 Diabetes

NCT07521475Type 2 Diabetes Mellitus

Insulet Corporation

Not applicable

350

California, Colorado, Florida, Georgia, Idaho, Illinois, Indiana, Massachusetts

2026-04-30

Recruiting

A Study of Seltorexant as Monotherapy in Adults and Elderly Participants With Major Depressive Disorder

NCT07573176Depressive Disorder, Major

DrugSeltorexant

Janssen Research & Development, LLC

Phase 3

600

Arkansas, California, Florida, Georgia, Illinois, Maryland, Massachusetts, Nevada

2026-04-30

Recruiting

FOLFIRI and Bevacizumab With or Without Pelareorep for Second-Line Treatment of Metastatic RAS-Mutated, Microsatellite-Stable Colorectal Cancer

NCT07446322Ras-mutated Metastatic Colorectal Cancer, mCRC, MSS Metastatic Colorectal Cancer

DrugsPelareorep·Avastin·Folfox·Bevacizumab

Oncolytics Biotech

Phase 2

Alabama, California, Florida, Georgia, Idaho, Illinois, Indiana, Michigan

2026-04-30

Recruiting

A Study to Assess Intravenous (IV) Telisotuzumab Adizutecan in Combination With Fluorouracil, Folinic Acid, and Oxaliplatin (FOLFOX) Compared to Standard of Care in Adult Participants With First-Line Metastatic Pancreatic Ductal Adenocarcinoma

NCT07490301Metastatic Pancreatic Ductal Adenocarcinoma, PDAC

DrugsTelisotuzumab Adizutecan·Fluorouracil·Irinotecan·Oxaliplatin

AbbVie

Phase 2/3

900

Connecticut, Illinois, Michigan, Missouri, Ohio, Pennsylvania, Texas, Virginia

2026-04-30

Recruiting

A Clinical Study of MK-1084 With Other Treatments for Non-small Cell Lung Cancer (MK-3475-01F)

NCT07286149Lung Neoplasm Malignant

DrugsCalderasib·Patritumab deruxtecan·Erbitux·Sacituzumab tirumotecan

Merck Sharp & Dohme LLC

Phase 1/2

140

Florida, Illinois, Oregon

2026-04-30

Recruiting

Correlation Between an Impedance Cardiography Test for Decompensation and the Development of Left Ventricular Replacement Fibrosis

NCT07230964Aortic Stenosis

Dermed Diagnostics, Inc.

Not applicable

Illinois

2026-04-30

Recruiting

A Study of Brenipatide (LY3537031) in Participants With Irritable Bowel Syndrome-Constipation (IBS-C)

NCT07545772Irritable Bowel Syndrome, Constipation

DrugBrenipatide

Eli Lilly and Company

Phase 2

342

Arizona, California, Florida, Illinois, Indiana, Kentucky, New York, Ohio

2026-04-29

By invitation

Open-Label Safety Study of AXS-14 in Subjects With Fibromyalgia

NCT07637162Fibromyalgia

DrugEsreboxetine

Axsome Therapeutics, Inc.

Phase 3

300

Arkansas, California, Connecticut, Florida, Georgia, Illinois, Kansas, Kentucky

2026-04-29

Recruiting

A Study to Learn About Salanersen's (BIIB115) Effects on Movement and Its Safety When Given Before Symptoms Appear in Babies With Genetically Diagnosed Spinal Muscular Atrophy (SMA)

NCT07221669Muscular Atrophy, Spinal

DrugSalanersen

Biogen

Phase 3

Illinois, Texas, Virginia

2026-04-28

Recruiting

U.S. Prospective Evaluation of EPIONE Device for Percutaneous MSK Procedures

NCT07325578Bone Tumor, Osteoporosis, Traumatic Fracture

Precision IO Group

Not applicable

California, Florida, Illinois

2026-04-28

Recruiting

Phase 2 Study to Assess the Safety and Efficacy of ANG003

NCT07450547Exocrine Pancreatic Insufficiency (EPI), Cystic Fibrosis (CF)

Anagram Therapeutics, Inc.

Phase 2

113

California, Colorado, Florida, Illinois, Iowa, Kansas, Kentucky, Maine

2026-04-24

Active, closed

ATI Evidence-based Guide Investigating Medical and Preventative Services

NCT04050319Sport Medicine

ATI Holdings, LLC

Observational

550,000

Illinois

2026-04-23

Recruiting

52-week Open Label Safety-Tolerability Study

NCT07369154Schizophrenia

DrugLB-102

LB Pharmaceuticals Inc.

Phase 3

900

Arizona, Arkansas, California, Florida, Georgia, Illinois, Maryland, Missouri

2026-04-23

Recruiting

A Phase 3 Study to Evaluate the Safety and Efficacy L606 in Participants With PH-ILD

NCT07285655Pulmonary Hypertension Due to Lung Disease (Disorder)

Liquidia Technologies, Inc.

Phase 3

344

Arizona, California, Colorado, Florida, Illinois, Indiana, New York, Oregon

2026-04-23

Recruiting

ROCKET-CLL Global Phase 3 Study: Rocbrutinib vs Pirtobrutinib in cBTKi-Pretreated R/R CLL/SLL

NCT07342478CLL / SLL, CLL (Chronic Lymphocytic Leukemia), CLL, Refractory, CLL, Relapsed

DrugsRocbrutinib·Pirtobrutinib

Newave Pharmaceutical Inc

Phase 3

306

Illinois, Maryland, Nevada, Ohio, Pennsylvania, Washington

2026-04-23

Recruiting

Study of Aritinercept in Patients With Generalized Myasthenia Gravis

NCT07596901Myasthenia Gravis, Generalized

Aurinia Pharmaceuticals Inc.

Phase 1/2

California, Florida, Illinois, Michigan, Texas

2026-04-22

Recruiting

A Phase III Trial of BNT324 Versus Docetaxel in Metastatic Castration-resistant Prostate Cancer

NCT07365995Metastatic Castration-resistant Prostate Cancer

DrugsBNT324·Prednisone/Prednisolone·Docetaxel

BioNTech SE

Phase 3

736

California, Colorado, Florida, Illinois, Maryland, New York, Ohio, Tennessee

2026-04-22

Active, closed

AMAZE 12: A Research Study Investigating How Well the Medicine NNC0487-0111 Helps People With Excess Body Weight Maintain Their Weight Loss

NCT07503210Obesity

DrugNNC0487-0111

Novo Nordisk A/S

Phase 3

606

Alabama, California, Florida, Illinois, Indiana, North Carolina, Pennsylvania, Rhode Island

2026-04-21

Recruiting

Study of Tarlatamab + ZL-1310 +/- Anti-programmed Death Ligand 1 (Anti-PD-L1) in Small Cell Lung Cancer (SCLC)

NCT07531095Small Cell Lung Cancer

DrugsZL-1310·Tarlatamab·Durvalumab

Amgen

Phase 1

160

Arizona, Florida, Illinois, Minnesota, New York, Tennessee, Virginia

2026-04-21

Recruiting

RE104 Safety and Efficacy Study in Generalized Anxiety Disorder

NCT07489651Generalized Anxiety Disorder

DrugRE104

Reunion Neuroscience Inc

Phase 2

160

Alabama, Arizona, Arkansas, California, Florida, Georgia, Illinois, Michigan

2026-04-20

Recruiting

Study to Evaluate the Efficacy and Safety of BMN 333 Versus Vosoritide in Children With Achondroplasia

NCT07441876Achondroplasia

DrugVosoritide

BioMarin Pharmaceutical

Phase 2/3

160

California, Delaware, Illinois, Maryland, Ohio, Pennsylvania, Texas

2026-04-20

Recruiting

AMAZE 6: A Research Study Investigating How Well the Medicine NNC0487-0111 Helps People With Excess Body Weight and Knee Osteoarthritis Lose Weight and Reduce Pain

NCT07509307Obesity, Overweight, Osteoarthritis, Knee

DrugNNC0487-0111

Novo Nordisk A/S

Phase 3

400

California, Connecticut, Florida, Illinois, Kentucky, Michigan, Missouri, New York

2026-04-20

Recruiting

A Phase 1 Safety and Dose Finding Study of GLIX1 in Adults With Recurrent or Progressive High-grade Glioma

NCT07464925Glioblastoma Multiforme of Brain, Glioma, Glioblastoma

Tetragon Biosciences Ltd

Phase 1

Florida, Illinois, New York

2026-04-20

Recruiting

A Research Study Comparing How Well Different Doses of the Medicine NNC0662-0419 Lower Blood Sugar in People With Type 2 Diabetes

NCT07415954Diabetes Mellitus, Type 2

DrugsNNC0662-0419·Semaglutide

Novo Nordisk A/S

Phase 2

270

California, Florida, Idaho, Illinois, Massachusetts, Missouri, North Carolina, Ohio

2026-04-17

Recruiting

A Study to Evaluate the Efficacy and Safety of Hetrombopag Olamine Tablets Vs Placebo in Patients With Chemotherapy-Induced Thrombocytopenia (ExCIT)

NCT07286032Patients With Chemotherapy-Induced Thrombocytopenia

DrugHetrombopag Olamine

Jiangsu HengRui Medicine Co., Ltd.

Phase 3

150

California, Florida, Illinois, Iowa, Mississippi, Nebraska, New Jersey, New York

2026-04-16

Recruiting

Novel Stretching Device Versus Night Splints

NCT05216679Plantar Fasciitis

SAE Orthopedics

Not applicable

100

Illinois

2026-04-15

Recruiting

A Clinical Trial of EYE201/MK-8748 in People With Macular Degeneration (MK-8748-003)

NCT07496567Macular Degeneration, Age-Related Macular Degeneration, Choroidal Neovascularization, Wet Macular Degeneration

DrugsTiespectus·Eylea·Aflibercept

EyeBiotech Ltd.

Phase 2/3

960

Arizona, California, Colorado, Connecticut, Florida, Illinois, Iowa, Kansas

2026-04-15

Recruiting

An Observational Study in Participants With Indolent Systemic Mastocytosis (ISM)

NCT07264959Indolent Systemic Mastocytosis

Blueprint Medicines Corporation

Observational

150

Colorado, Illinois, Maryland, Massachusetts, Michigan, Missouri, Utah

2026-04-15

Recruiting

Randomized Study on Transoral Outlet Reduction and Lifestyle Changes for Weight Regain After Gastric Bypass

NCT07015424Weight Regain, Weight Loss

Boston Scientific Corporation

Not applicable

108

California, Florida, Illinois, Maryland, Minnesota, New York, Texas, West Virginia

2026-04-14

Recruiting

Evaluation of IV AMBTX-01 (Neridronate) for Treatment of CRPS Type 1 (CRPS-RISE)

NCT07210515Complex Regional Pain Syndrome Type I

DrugNeridronate

Ambros Therapeutics, Inc.

Phase 3

270

Arizona, Arkansas, California, District of Columbia, Florida, Georgia, Illinois, Kansas

2026-04-14

Recruiting

A Study to See if Giving Fianlimab and Cemiplimab Together is Better Than Cemiplimab Alone at Treating Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma

NCT06769698Head and Neck Squamous Cell Carcinoma (HNSCC)

DrugCemiplimab

Regeneron Pharmaceuticals

Phase 2

120

California, Florida, Georgia, Illinois, Kentucky, Michigan, Nebraska, New York

2026-04-14

Recruiting

A Study to Evaluate the Treatment Outcomes of Subcutaneous Anifrolumab in Immunosuppressant-naïve and Biologic-naïve Systemic Lupus Erythematosus

NCT07430306Systemic Lupus Erythematosus

DrugAnifrolumab

AstraZeneca

Phase 3

245

Alabama, Arizona, California, Florida, Illinois, Indiana, Louisiana, Maryland

2026-04-13

Recruiting

Pharmacokinetic and Early Efficacy of OPT101 in Patients With Type 1 Diabetes Mellitus

NCT06964087Type I Diabetes

DrugOPT101

Op-T LLC

Phase 2

Alabama, California, Colorado, Illinois, Washington

2026-04-10

Recruiting

A Study to Investigate Abdominal Symptoms With Camlipixant Compared With Placebo in Adults With Irritable Bowel Syndrome - Diarrhea (IBS-D) and Irritable Bowel Syndrome - Mixed (IBS-M)

NCT07519395Irritable Bowel Syndrome

DrugCamlipixant

GlaxoSmithKline

Phase 2

420

Alabama, Arizona, California, Colorado, Florida, Georgia, Idaho, Illinois

2026-04-08

Recruiting

AMG 436 as Monotherapy and Combination Therapy in Participants With MSI-H/dMMR Solid Tumors

NCT07403721Metastatic or Locally Advanced Solid Tumors With Microsatellite Instability-high (MSI-H) or Mismatched Repair Deficiency (dMMR)

Amgen

Phase 1

464

California, Illinois, Indiana, Maine, Tennessee, Texas

2026-04-08

Recruiting

A Study to Evaluate the Long-term Safety and Tolerability of Xanomeline and Trospium Chloride for the Treatment of Psychiatric Disorders in Children and Adolescents

NCT07424404Schizophrenia, Autism-Related Irritability

DrugsKarX-EC·KarXT

Karuna Therapeutics, Inc., a Bristol Myers Squibb company

Phase 3

400

Alabama, Arizona, California, Connecticut, Florida, Georgia, Illinois, Kentucky

2026-04-07

Active, closed

Efficacy and Safety of Oral KAI-7535 in Adult Participants Living With Obesity or Overweight With at Least 1 Weight-Related Comorbidity

NCT07497880Obesity, Overweight

Kailera

Phase 2

306

Arizona, California, Connecticut, Florida, Georgia, Illinois, Indiana, Louisiana

2026-04-06

Not yet open

Extensively Hydrolyzed Formula Growth Monitioring Study (GMS)

NCT07513506Growth

Mead Johnson Nutrition

Not applicable

214

Alabama, Arkansas, Florida, Illinois, Kentucky, North Carolina, Tennessee, Texas

2026-04-03

Recruiting

An Evaluation of the Safety and Efficacy of TSND-201 for the Treatment of PTSD (EMPOWER-1)

NCT07456696Post Traumatic Stress Disorder

DrugMethylone

Transcend Therapeutics

Phase 3

300

Arizona, Arkansas, California, Colorado, Florida, Georgia, Illinois, Louisiana

2026-04-02

Recruiting

A Study Evaluating Disease Characteristics and Outcomes in Participants With Asthma in Routine Clinical Practice

NCT07556159Asthma

Sanofi

Observational

2,500

Alabama, Arizona, California, Florida, Georgia, Illinois, Kentucky, Maryland

2026-04-01

Recruiting

Achilles Tendinopathy Embolization

NCT07477860Achilles Tendinopathy (AT)

Joint & Vascular Institute

Phase 1

Illinois

2026-04-01

Recruiting

A Long-Term Open-Label Study of ML-007C-MA in Adults With Schizophrenia

NCT07459647Schizophrenia

DrugML-007C-MA

MapLight Therapeutics

Phase 2

500

Arkansas, California, Florida, Georgia, Illinois, Maryland, Massachusetts, Michigan

2026-03-31

Recruiting

AVA6103 in Subjects With Locally Advanced or Metastatic Selected Solid Tumors

NCT07454642Vulvar Adenocarcinoma, PDAC - Pancreatic Ductal Adenocarcinoma, Gastric Adenocarcinoma, GEJ Adenocarcinoma

Avacta Life Sciences Ltd

Phase 1

174

Arizona, Florida, Illinois, Michigan, New York, Texas, Virginia

2026-03-31

Recruiting

A Clinical Study of Letermovir (MK-8228) in Children and Adolescents Who Receive a Kidney Transplant (KT) (MK-8228-077)

NCT07199465Cytomegalovirus Prophylaxis

DrugLetermovir

Merck Sharp & Dohme LLC

Phase 1

Alabama, California, Colorado, Florida, Georgia, Illinois, Michigan, Minnesota

2026-03-30

Recruiting

A Safety and Efficacy Study of hu14 in High-Risk Neuroblastoma Patients

NCT07549321High-Risk Neuroblastoma

DrugsTemozolomide·Irinotecan

Renaissance Pharma Ltd.

Phase 2/3

144

California, Colorado, Illinois, Minnesota, New York, North Carolina, Pennsylvania, Texas

2026-03-30

Recruiting

A Clinical Trial of EYE201/MK-8748 in People With Macular Degeneration (MK-8748-002)

NCT07440225Macular Degeneration, Age-Related Macular Degeneration, Choroidal Neovascularization, Wet Macular Degeneration

DrugsTiespectus·Eylea·Aflibercept

EyeBiotech Ltd.

Phase 2/3

960

Arizona, Arkansas, California, Florida, Illinois, Indiana, Maryland, Michigan

2026-03-27

Recruiting

LY4268989 in Adults With Moderately to Severely Active Ulcerative Colitis

NCT07415044Ulcerative Colitis (UC), Ulcerative Colitis, Active Moderate, Ulcerative Colitis, Active Severe

DrugZotemtegrast

Eli Lilly and Company

Phase 2

1,431

Arizona, California, Colorado, Connecticut, Florida, Idaho, Illinois, Indiana

2026-03-26

Recruiting

A Multi Center Study Testing a New Implant for Adults With Severe Emphysema

NCT07119229Emphysema or COPD, Emphysema, COPD

Pulmair Medical, Inc.

Not applicable

California, Illinois, Massachusetts, Wisconsin

2026-03-25

Recruiting

Transition to KPL-387 Monotherapy Dosing & Administration Study

NCT07288216Recurrent Pericarditis, Heart Diseases, Pericarditis

DrugKPL-387

Kiniksa Pharmaceuticals International, plc

Phase 2

120

Arizona, California, Florida, Illinois, Maryland, Massachusetts, Minnesota, Missouri

2026-03-25

Recruiting

Study to Evaluate LB-102 for the Treatment of Adult Patients With Acute Schizophrenia

NCT07363577Schizophrenia

DrugLB-102

LB Pharmaceuticals Inc.

Phase 3

456

Arkansas, California, Florida, Georgia, Illinois, Missouri, Ohio

2026-03-25

Recruiting

A Clinical Study to Evaluate the Effects of Enicepatide (RO7795068) in Participants With Obesity or Overweight and Type 2 Diabetes

NCT07351058Obesity or Overweight, Type 2 Diabetes Mellitus

Hoffmann-La Roche

Phase 3

1,600

Alabama, Arizona, California, District of Columbia, Florida, Georgia, Idaho, Illinois

2026-03-23

Recruiting

PODOMOUNT-Basket, a Study to Test Whether BI 764198 Helps Adults and Adolescents With Different Types of Kidney Disease

NCT07355296Proteinuric Kidney Diseases

DrugApecotrep

Boehringer Ingelheim

Phase 2

132

Alabama, California, Colorado, Florida, Illinois, Maryland, Michigan, New York

2026-03-23

By invitation

Evaluation of the Safety and Performance of a Bioresorbable Nasal Dressing Containing Mometasone Furoate (MF)

NCT07286201Chronic Rhinosinusitis (CRS), Chronic Rhinosinusitis (CRS) With and Without Nasal Polyps

Polyganics BV

Not applicable

110

Colorado, Georgia, Illinois, Louisiana, Maryland, South Carolina, Texas, Utah

2026-03-19

Recruiting

Dose Ranging Study of ORKA-002 in Patients With Moderate-to-Severe Plaque Psoriasis

NCT07474792Plaque Psoriasis

DrugORKA-002

Oruka Therapeutics, Inc.

Phase 2

160

Alabama, Arizona, California, Connecticut, Florida, Illinois, Massachusetts, Michigan

2026-03-19

Recruiting

Visugromab, Nivolumab and Lenvatinib Compared to Double Placebo and Lenvatinib in Unresectable or Metastatic Hepatocellular Carcinoma Post Anti-PD-(L)1 Failure

NCT07219459Unresectable or Metastatic Hepatocellular Carcinoma, Child-Pugh A Hepatocellular Carcinoma, Failure of First-Line Treatment That Included an Approved Anti PD-(L)1 Compound

DrugsVisugromab RDE·Opdivo·Lenvatinib·Nivolumab

CatalYm GmbH

Phase 2

104

California, Georgia, Illinois, Massachusetts

2026-03-19

Recruiting

A Phase 2/3 Study of Brepocitinib in Adults With Lichen Planopilaris

NCT07532603Lichen Planopilaris

DrugBrepocitinib

Priovant Therapeutics, Inc.

Phase 2/3

342

Alabama, Arizona, California, Colorado, Connecticut, Florida, Illinois, Indiana

2026-03-19

Recruiting

A Study to Investigate Ubamatamab With and Without Marlotamig (REGN7075) in Adult Participants With Advanced/Metastatic Non-Small Cell Lung Cancer (NSCLC)

NCT07154290Non Small Cell Lung Cancer, Advanced Non Small Cell Lung Cancer, Metastatic Non Small Cell Lung Cancer, Carcinoma Non Small Cell Lung

DrugsMarlotamig·Ubamatamab·Sarilumab

Regeneron Pharmaceuticals

Phase 2

300

Alabama, Arizona, California, Delaware, District of Columbia, Florida, Illinois, Indiana

2026-03-18

Recruiting

A Phase 3 Trial to Compare IV BCV Versus IV CDV for Treatment of Adenovirus Infection After Allo-HCT

NCT07387367Adenovirus Infections

SymBio Pharmaceuticals

Phase 3

180

Arizona, California, Colorado, District of Columbia, Florida, Georgia, Illinois, Indiana

2026-03-17

Recruiting

Implementation Study of Lenacapavir Pre-exposure Prophylaxis for HIV Prevention

NCT07473778HIV Infections

DrugsF/TAF·Emtricitabine/tenofovir disoproxil fumarate·Descovy·F/TDF

Gilead Sciences

Observational

3,000

Alabama, California, Colorado, Florida, Georgia, Illinois, Louisiana, Maryland

2026-03-17

Recruiting

A Study to Evaluate the Safety and Tolerability of Pumitamig Alone or In Combination With Ipilimumab in Participants With First-Line Advanced or Unresectable Hepatocellular Carcinoma (HCC) (ROSETTA HCC-206)

NCT07291076Hepatocellular Carcinoma (HCC)

DrugsPumitamig·Yervoy·Ipilimumab

Bristol-Myers Squibb

Phase 1/2

198

California, Illinois, Michigan, New Jersey, New York, Oregon, Tennessee, Washington

2026-03-16

Recruiting

Efficacy and Safety Study of Ixoberogene Soroparvovec (Ixo-vec) in Participants With Neovascular Age-related Macular Degeneration (AQUARIUS)

NCT07482176Neovascular Age-Related Macular Degeneration (nAMD), Wet AMD

DrugAflibercept

Adverum Biotechnologies, Inc.

Phase 3

534

Arizona, Arkansas, California, Colorado, Connecticut, Florida, Georgia, Illinois

2026-03-16

Recruiting

The Use of p48/64 MW HPC Flow Modulation Device in the Treatment of Wide-necked Intracranial Aneurysms

NCT07143019Hemorrhagic Stroke, Aneurysm, Intracranial, Saccular Aneurysm, Fusiform Aneurysm

phenox Inc.

Not applicable

214

Arizona, California, Colorado, Florida, Georgia, Illinois, Iowa, Massachusetts

2026-03-16

Recruiting

A Clinical Study to Evaluate the Effects of Enicepatide (RO7795068) in Participants With Obesity or Overweight Without Type 2 Diabetes

NCT07351045Obesity or Overweight

Hoffmann-La Roche

Phase 3

2,000

Alabama, Arizona, California, Connecticut, Georgia, Hawaii, Illinois, Kentucky

2026-03-16

Recruiting

Study to Assess the Safety, Tolerability, and Treatment Response of GXV813 in Hospitalized Adults With Schizophrenia

NCT07467993Schizophrenia

Novartis Pharmaceuticals

Phase 2

142

Arkansas, California, Florida, Georgia, Illinois, Missouri

2026-03-16

Recruiting

A Study to Evaluate Pumitamig Versus Durvalumab Following Concurrent Chemoradiation Therapy in Participants With Unresectable Stage III Non-small Cell Lung Cancer (NSCLC) (ROSETTA Lung-201)

NCT07361497Non-small Cell Lung Cancer (NSCLC)

DrugsPumitamig·Durvalumab

Bristol-Myers Squibb

Phase 3

850

Alabama, Colorado, Delaware, Florida, Georgia, Illinois, Indiana, Kentucky

2026-03-16

Recruiting

A Study of MUC16-Directed Antibody Drug Conjugate HWK-016 in Participants With Advanced Solid Tumors.

NCT07470853PROC, Platinum Resistant Ovarian Cancer, Endometrial Cancer

DrugBevacizumab

Whitehawk Therapeutics, Inc.

Phase 1

265

Arkansas, California, Florida, Illinois, Michigan, New York, North Carolina, Ohio

2026-03-15

Recruiting

A Study to Investigate the Efficacy and Safety of Frexalimab Versus Tacrolimus in Adults Undergoing Kidney Transplantation

NCT07412470Kidney Transplant Rejection

DrugsRabbit anti-thymocyte globulin·Frexalimab·Mycophenolate Mofetil·Tacrolimus

Sanofi

Phase 2/3

526

California, Georgia, Illinois, Kansas, Maryland, Massachusetts, Michigan, New York

2026-03-13

Recruiting

A Study to Evaluate the Safety and Efficacy of Pumitamig in Combination With Chemotherapy Versus Nivolumab in Combination With Chemotherapy in Participants With Previously Untreated Advanced or Metastatic Gastric, Gastroesophageal Junction, or Esophageal Adenocarcinoma (ROSETTA Gastric-204)

NCT07221149Untreated Advanced or Metastatic Gastric, Gastroesophageal Junction, or Esophageal Adenocarcinoma

DrugsPumitamig·Folfox·Nivolumab

Bristol-Myers Squibb

Phase 2/3

690

Arizona, California, Florida, Georgia, Illinois, Iowa, Minnesota, Missouri

2026-03-13

By invitation

Long-Term Open-Label Extension Study of Oral Levosimendan

NCT07436689Pulmonary Hypertension Associated With HFpEF

DrugTNX-103

Tenax Therapeutics, Inc.

Phase 3

800

Illinois, Massachusetts, Minnesota, Missouri, Nebraska, North Carolina, South Carolina, Wisconsin

2026-03-13

Active, closed

How Fig Polyphenols Affect Blood Sugar and Insulin Levels After Eating in Adults at Risk for Diabetes

NCT07625046Pre Diabetic

Clinical Nutrition Research Center, Illinois Institute of Technology

Not applicable

Illinois

2026-03-12

Active, closed

Evaluation of the Safety and Efficacy of Dehydrated Human Placenta Tissue (dHPT) for Wound Healing

NCT07375160Diabetic Foot Ulcer (DFU), Venous Leg Ulcer (VLU), Pressure Ulcer (PU)

Cellution Biologics

Observational

300

Illinois

2026-03-12

Recruiting

A Study to Find Out if Enfortumab Vedotin Given With Pembrolizumab Helps People With Muscle-invasive Bladder Cancer Keep Their Bladder

NCT07475806Muscle-invasive Bladder Cancer

DrugsEnfortumab Vedotin·Pembrolizumab

Astellas Pharma Global Development, Inc.

Phase 2

240

Arkansas, Illinois, Indiana, Michigan, New Jersey, New York, Pennsylvania, South Carolina

2026-03-12

Recruiting

A Study to Evaluate the Efficacy of Pumitamig Versus Pembrolizumab in Participants With Previously Untreated Advanced Non-Small Cell Lung Cancer and PD-L1 ≥ 50%. (ROSETTA Lung-202)

NCT07361510Non-Small Cell Lung Cancer (NSCLC)

DrugsPumitamig·Pembrolizumab

Bristol-Myers Squibb

Phase 3

750

Alabama, Arizona, California, Colorado, Florida, Georgia, Illinois, Indiana

2026-03-12

Recruiting

Phase 3 Pivotal Trial Comparing CARTISTEM® and Surgical Comparator for Knee Cartilage Lesions and Osteoarthritis

NCT07339111Knee Cartilage Defects

Medipost, Inc.

Phase 3

300

Alabama, Arizona, California, Colorado, Illinois, Kentucky, Louisiana, Michigan

2026-03-11

Recruiting

Symbiotic-GU-06: A Study to Learn About PF-08634404 Alone or In Combination With Enfortumab Vedotin in Urothelial Cancer

NCT07421700Urothelial Cancer, Advanced/Metastatic Urothelial Cancer, Urothelial Carcinoma

DrugsPF-08634404·Enfortumab Vedotin

Pfizer

Phase 1/2

132

Arkansas, California, Colorado, Connecticut, District of Columbia, Georgia, Illinois, Maryland

2026-03-11

Recruiting

A Phase IIb Dose-ranging Study to Assess the Efficacy and Safety of GIA632 in Participants With Non-segmental Vitiligo

NCT07431177Non-segmental Vitiligo

DrugGIA632

Novartis Pharmaceuticals

Phase 2

210

Alabama, California, Florida, Illinois, Indiana, Maryland, Michigan, Nebraska

2026-03-09

Recruiting

Evaluation of the Efficacy and Safety of THRV-1268 in Participants With Long QT Syndrome Type 2 (LQTS2) and Type 3 (LQTS3)

NCT07277582Long QT Syndrome (LQTS) 2

Thryv Therapeutics, Inc.

Phase 2/3

Arizona, California, Illinois, Massachusetts, Michigan, Minnesota, New York, North Carolina

2026-03-07

Recruiting

A Study of Nipocalimab in Adults With Moderate to Severe Systemic Lupus Erythematosus

NCT07438496Lupus Erythematosus, Systemic

DrugNipocalimab

Janssen Research & Development, LLC

Phase 3

600

California, Colorado, Florida, Georgia, Illinois, Louisiana, Michigan, New Jersey

2026-03-05

Recruiting

A Study of IDE892 as Monotherapy and Combination in MTAP-deleted Advanced Solid Tumors

NCT07277413NSCLC Adenocarcinoma, Gastroesophageal Cancer (GC), Gastric Adenocarcinoma, Adenocarcinoma of Esophagus

DrugIDE397

IDEAYA Biosciences

Phase 1

260

Arizona, California, District of Columbia, Florida, Illinois, Minnesota, Nebraska, New Jersey

2026-03-04

Active, closed

Efficacy and Safety of Ribupatide (KAI-9531) Administered Once Weekly in Participants Living With Obesity Who Do Not Have Diabetes

NCT07458269Obesity

DrugRibupatide

Kailera

Phase 2

264

Arizona, California, Florida, Georgia, Illinois, Indiana, Kentucky, Maryland

2026-03-04

Recruiting

A Study to Investigate OCS Tapering in Adult Participants With Generalized Myasthenia Gravis Treated With Ravulizumab

NCT07221838Generalized Myasthenia Gravis, gMG

DrugsPrednisone/Prednisolone·Ravulizumab

Alexion Pharmaceuticals, Inc.

Phase 4

Illinois, New Jersey, North Carolina, Tennessee

2026-03-04

Active, closed

LEVEL-2: LEVosimendan to Improve Exercise Limitation in Patients With PH-HFpEF-2

NCT07288398Pulmonary Hypertension Associated With HFpEF

DrugTNX-103

Tenax Therapeutics, Inc.

Phase 3

540

Alabama, Arizona, California, Georgia, Illinois, Indiana, Louisiana, Massachusetts

2026-03-03

Recruiting

A Study of the Feasibility, Safety and Tolerability of Aticaprant as Adjunctive Treatment in Participants With Schizophrenia

NCT07615426Schizophrenia

Janssen Research & Development, LLC

Phase 1

California, Georgia, Illinois, Michigan, New York, Texas

2026-03-02

Not yet open

Inhibition of Aggressive Behavior in Participants With Fragile X Syndrome

NCT07328529Aggressive Behavior in Fragile X Syndome

Azevan Pharmaceuticals

Phase 2

California, Illinois, Ohio

2026-03

Recruiting

COPD Exacerbation Follow Up

NCT07118306COPD (Chronic Obstructive Pulmonary Disease)

Viz.ai, Inc.

Observational

485

Illinois, New Jersey, Pennsylvania, Virginia, Wisconsin

2026-02-27

Recruiting

A Study to Evaluate Adverse Events, Change in Disease Activity, Tolerability, and How Intravenous ABBV-438 Moves Through the Body in Adult Participants With Multiple Myeloma (MM)

NCT07409246Multiple Myeloma

AbbVie

Phase 1

127

California, Colorado, Florida, Georgia, Illinois, Michigan

2026-02-27

Recruiting

Phase 3 Study of Telitacicept in Active Primary Sjögren's Disease

NCT07404865Primary Sjogren's Disease

DrugTelitacicept

Vor Biopharma

Phase 3

250

Arizona, California, Colorado, Florida, Idaho, Illinois, Louisiana, Maryland

2026-02-26

Recruiting

Effectiveness and Adverse-effect Switch Evaluation of Xanomeline and Trospium Chloride (KarXT)

NCT07379827Schizophrenia

DrugKarXT

Bristol-Myers Squibb

Observational

1,500

Arkansas, California, Florida, Georgia, Illinois, Michigan, Minnesota, Nebraska

2026-02-26

Active, closed

Intravascular Neuro OCT Imaging System for Aneurysm Treatment Evaluation

NCT07214220Intracranial Aneurysm

Spryte Medical

Not applicable

Florida, Illinois, Massachusetts, New York

2026-02-25

Recruiting

Evaluate the Clinical Performance of the Flow Cytometry - FlowPath Lung Test as a Sensitive and Specific Non-invasive Diagnostic of Sputum Samples to Identify/Detect the Presence of Lung Cancer in High-risk Individuals Who Have Existing Lung Nodules, 6 to <30 mm in Diameter, Determined by LDCT.

NCT07168993Lung Cancer (Diagnosis)

bioAffinity Technologies Inc.

Not applicable

2,063

California, Colorado, Florida, Illinois, Ohio, Pennsylvania, Texas, Wisconsin

2026-02-25

Recruiting

AMAZE 1: A Research Study Investigating How Well the Medicine NNC0487-0111 Helps People With Excess Body Weight Lose Weight

NCT07339423Obesity

DrugNNC0487-0111

Novo Nordisk A/S

Phase 3

1,150

Florida, Georgia, Illinois, Indiana, Missouri, New York, North Carolina, Pennsylvania

2026-02-24

Active, closed

ATI Evidence-based Guide Investigating Clinical Services

NCT02285868Primary Body Region (Arranged Most Common to Least), Lumbar/SI, Knee, Shoulder

ATI Holdings, LLC

Observational

4,000,000

Illinois

2026-02-24

Recruiting

Clinical Assessment of Response in the Treatment of Depression With Daytime Sleepiness Using Solriamfetol

NCT07484217Major Depressive Disorder With Excessive Daytime Sleepiness Symptoms

DrugSolriamfetol

Axsome Therapeutics, Inc.

Phase 3

508

Arizona, California, Florida, Georgia, Illinois, Maryland, Massachusetts, Nevada

2026-02-23

Recruiting

An Open-Label Extension Study of ORKA-001 in Participants With Plaque Psoriasis

NCT07449702Plaque Psoriasis

DrugORKA-001

Oruka Therapeutics, Inc.

Phase 2

240

Arizona, California, Connecticut, Florida, Illinois, Kentucky, Maryland, Massachusetts

2026-02-23

Recruiting

A Study Comparing AZD0120, a Dual-targeted CAR-T Against B-cell Maturation Antigen (BCMA) and CD19, Versus Standard Regimens in Participants With Relapsed Refractory Multiple Myeloma (DURGA-4)

NCT07391657Relapsed Refractory Multiple Myeloma

DrugsAZD0120·Darzalex·Velcade·Carfilzomib

AstraZeneca

Phase 3

508

Arizona, California, Colorado, Connecticut, District of Columbia, Florida, Georgia, Illinois

2026-02-23

Recruiting

A Study to Learn How Stargardt-type Eye Conditions Progress in Children and Adults

NCT07425574Stargardt Disease, Stargardt Macular Dystrophy, Stargardt-like Macular Dystrophy

Astellas Pharma Global Development, Inc.

Observational

Arizona, California, Florida, Illinois, Michigan, Mississippi, North Carolina, Ohio

2026-02-20

Active, closed

A Clinical Study to Evaluate the Efficacy and Safety of Ultra in Promoting Hair Regrowth

NCT07588243Androgenic Alopecia

CynosureLutronic

Not applicable

Illinois, Massachusetts

2026-02-19

Active, closed

A Study to Assess the Effectiveness and Safety of IPN10200 Over Time in Adults With Moderate to Severe Wrinkle-like Lines Between the Eyebrows

NCT07435428Moderate to Severe Glabellar Lines

DrugCorabotase

Ipsen

Phase 3

1,300

California, Connecticut, District of Columbia, Florida, Georgia, Illinois, Indiana, Louisiana

2026-02-18

Recruiting

A Chronic Pain Master Protocol (CPMP): A Study of LY4065967 in Participants With Diabetic Peripheral Neuropathic Pain

NCT07285018Diabetic Peripheral Neuropathic Pain

DrugLY4065967

Eli Lilly and Company

Phase 2

150

Alabama, Arizona, California, Connecticut, Florida, Georgia, Illinois, Louisiana

2026-02-16

Active, closed

COMO: A Phase 3 Randomized, Double-Masked Study Comparing the Efficacy of EYP-1901 Against Aflibercept in DME

NCT07449936Diabetic Macular Edema, DME, Diabetic Macular Edema (DME)

DrugsEYP-1901·Aflibercept

EyePoint Pharmaceuticals, Inc.

Phase 3

240

California, Colorado, Florida, Georgia, Hawaii, Illinois, Indiana, Louisiana

2026-02-16

Recruiting

A Clinical Trial of Sac-TMT in People With Non-HRD Positive Advanced Ovarian Cancer (MK-2870-021)

NCT07318558Ovarian Neoplasms, Ovarian Cancer

DrugsMvasi·Sacituzumab tirumotecan·Avastin·Bevacizumab

Merck Sharp & Dohme LLC

Phase 3

900

Alabama, California, Florida, Georgia, Illinois, Indiana, Louisiana, Maine

2026-02-16

Recruiting

A Study to Find Out if BI 764198 Helps Adults and Adolescents With a Kidney Condition Called Focal Segmental Glomerulosclerosis (FSGS)

NCT07220083Focal Segmental Glomerulosclerosis

DrugApecotrep

Boehringer Ingelheim

Phase 3

286

Alabama, Arizona, California, Colorado, District of Columbia, Florida, Georgia, Illinois

2026-02-16

Recruiting

A Study of Brenipatide in Participants With Opioid Use Disorder

NCT07420283Opioid Use Disorder

DrugsBuprenorphine·Brenipatide

Eli Lilly and Company

Phase 2

465

Arizona, Arkansas, California, Florida, Illinois, Indiana, Kentucky, Maryland

2026-02-13

Recruiting

A Trial to Investigate Safety, Exposure, and Efficacy of HU6 Compared With Placebo in Adult Participants With Metabolic Dysfunction-associated Steatohepatitis (MASH)

NCT07491458MASH - Metabolic Dysfunction-Associated Steatohepatitis

DrugHU6

Rivus Pharmaceuticals, Inc.

Phase 2

180

Arizona, Arkansas, California, Florida, Illinois, Louisiana, Michigan, Minnesota

2026-02-13

Recruiting

Aspiration Thrombectomy Using the Symphony or Prodigy System

NCT07350499Arterial Thromboembolism, Venous Thromboembolism, Pulmonary Embolism

Imperative Care, Inc.

Observational

750

Alabama, Florida, Illinois, Indiana, Michigan, New York, North Carolina, Ohio

2026-02-13

Recruiting

A Study of the Efficacy and Safety of Danicamtiv in Participants With Symptomatic Genetic and Familial Dilated Cardiomyopathy

NCT07210723Symptomatic Genetic Dilated Cardiomyopathy

DrugDanicamtiv

Kardigan, Inc.

Phase 2/3

332

Alabama, California, District of Columbia, Florida, Illinois, Louisiana, Maryland, Massachusetts

2026-02-13

Recruiting

Rifaximin 200 mg Plus Oral Rehydration vs Oral Rehydration Alone in Children With Acute Diarrhea

NCT07285785Diarrhea, Gastroenteritis, Bacterial Infection, Acute Diarrhea

DrugRifaximin

Bausch Health Americas, Inc.

Phase 4

California, Florida, Georgia, Illinois, Oregon, Texas, Virginia

2026-02-11

Recruiting

Efficacy And Safety Evaluation of Glepaglutide in Treatment of SBS

NCT07197944Short Bowel Syndrome

DrugGlepaglutide

Zealand Pharma

Phase 3

Illinois, Missouri, Nebraska, New York, Pennsylvania, Tennessee

2026-02-11

Recruiting

A Phase 2b Study Evaluating Oral VH4524184 Regimens in Treatment Naïve Persons With HIV-1 (INNOVATE Study)

NCT07202546HIV Infections

DrugsVH4524184·Dovato·Dolutegravir/Lamivudine

ViiV Healthcare

Phase 2

186

California, Colorado, Connecticut, Florida, Georgia, Illinois, Kentucky, Missouri

2026-02-11

Recruiting

A Study of Eloralintide (LY3841136) in Participants With Persistent Obesity Who Are Treated With a Weekly Incretin

NCT07392190Overweight, Obesity

DrugEloralintide

Eli Lilly and Company

Phase 3

900

Alabama, Arizona, California, Connecticut, Florida, Georgia, Idaho, Illinois

2026-02-10

Recruiting

Symbiotic-GU-08: A Study to Learn About the Medicine Called PF-08634404 Dosed Alone and in Combination With Other Anticancer Therapies in Adults With Locally Advanced or Metastatic Renal Cell Cancer

NCT07227415Carcinoma, Renal Cell, Advanced Renal Cell Carcinoma, Renal Cancer, Renal Neoplasm

DrugsCasdatifan·PF-08634404·Axitinib·Yervoy

Pfizer

Phase 1/2

224

Arizona, Arkansas, California, Colorado, Florida, Georgia, Illinois, Massachusetts

2026-02-10

Recruiting

A Study of Brenipatide in Adult Participants With Schizophrenia

NCT07410507Schizophrenia

DrugBrenipatide

Eli Lilly and Company

Phase 2

450

Arkansas, California, Connecticut, Florida, Georgia, Illinois, Maryland, Massachusetts

2026-02-10

Active, closed

A Multicenter, Randomized, Double-Masked, Placebo-Controlled Pilot Study to Evaluate the Efficacy and Safety of ZOC2017217 in Subjects With Age-Related Cataract

NCT07395986Age Related Cataracts

Ocusun Ophthalmic Pharmaceutical (Guangzhou) Co., Ltd.

Phase 2

Arizona, California, Colorado, Florida, Georgia, Illinois, North Carolina, North Dakota

2026-02-10

Recruiting

Efficacy and Safety of Eloralintide (LY3841136) in Participants With Osteoarthritis Knee Pain and Obesity or Overweight

NCT07353931Osteoarthritis, Overweight or Obesity

DrugEloralintide

Eli Lilly and Company

Phase 3

900

Alabama, Arizona, California, Colorado, Florida, Georgia, Idaho, Illinois

2026-02-09

Recruiting

A Double-blind, Randomized Controlled Trial to Investigate the Efficacy, Safety, and Pharmacokinetics of Pegloticase Administration Via Subcutaneous and Intravenous Routes Both With Methotrexate in Participants With Uncontrolled Gout

NCT07388498Uncontrolled Gout

DrugMethotrexate

Amgen

Phase 3

270

Alabama, Alaska, California, Colorado, Florida, Georgia, Idaho, Illinois

2026-02-09

Recruiting

KEYMAKER-U04 Substudy 04D: A Clinical Study of New Treatments Given With Enfortumab Vedotin and Pembrolizumab in People With Urothelial Cancer (MK-3475-04D/KEYMAKER-U04)

NCT07232602Bladder Cancer

DrugsMK-3120·Enfortumab Vedotin·Keytruda·Pembrolizumab

Merck Sharp & Dohme LLC

Phase 1/2

California, Illinois, New York, Ohio, Utah

2026-02-09

Recruiting

A Clinical Trial Investigating the Safety and Biological Activity of the Antibody BNT351 in Adults Living Without and With HIV

NCT07392372HIV -1 Infection

BioNTech SE

Phase 1

Illinois, Maryland, Missouri, New York

2026-02-09

Active, closed

CAPRI: A Phase 3 Randomized, Double-Masked Study Comparing the Efficacy of EYP-1901 Against Aflibercept in DME

NCT07449923Diabetic Macular Edema, DME, Diabetic Macular Edema (DME)

DrugsEYP-1901·Aflibercept

EyePoint Pharmaceuticals, Inc.

Phase 3

240

Arizona, California, Colorado, Connecticut, Florida, Illinois, Indiana, Kentucky

2026-02-09

Active, closed

A Study of JNJ-79635322 in Participants With Relapsed or Refractory Multiple Myeloma

NCT07266441Multiple Myeloma

DrugRamantamig

Janssen Research & Development, LLC

Phase 2

168

Alabama, Arizona, California, Colorado, Florida, Georgia, Illinois, Iowa

2026-02-08

Recruiting

A Study of CX11 Tablets in Patients With Type 2 Diabetes Mellitus

NCT07340320Type II Diabetes Mellitus

DrugCX11

Corxel Pharmaceuticals

Phase 2

240

Alabama, California, Florida, Georgia, Illinois, Indiana, Maryland, Massachusetts

2026-02-06

Recruiting

A Study to Learn About the Effects of Cemsidomide in Combination With Elranatamab in Relapsed/Refractory Multiple Myeloma Subjects

NCT07280013Multiple Myeloma (MM)

DrugsCemsidomide·Elranatamab

C4 Therapeutics, Inc.

Phase 1

Arizona, California, Florida, Georgia, Illinois, Indiana, Kentucky, Maryland

2026-02-06

Recruiting

A Prospective, Post-Market, Clinical Follow-up Study of the Incompass™ Total Ankle System

NCT07118501Post Traumatic Arthritis, Osteoarthritis, Total Ankle Replacement, Total Ankle Prosthesis

Stryker Trauma and Extremities

Observational

200

Illinois, Indiana, Kentucky, Oregon, South Carolina

2026-02-06

Recruiting

A Study to Evaluate the Efficacy, Safety, and Tolerability of VIM0423 in Individuals With Isolated Dystonia

NCT07304089Dystonia

DrugVIM0423

Vima Therapeutics

Phase 2

100

Alabama, Arizona, California, Colorado, Florida, Georgia, Illinois, Kansas

2026-02-05

Recruiting

Study of AGN-151607-DP to Assess Adverse Events and Change in Disease Activity in Adult Participants Undergoing Open Abdominal Ventral Hernia Repair

NCT07226791Ventral Hernia

DrugAGN-151607-DP

AbbVie

Phase 2

200

California, Florida, Illinois, Kansas, Minnesota, North Carolina, Ohio, Pennsylvania

2026-02-04

Recruiting

A Study Comparing JNJ-79635322 and an Anti-B-cell Maturation Antigen (BCMA)xCD3 Bispecific Antibody in Participants With Relapsed or Refractory Multiple Myeloma

NCT07258511Multiple Myeloma

DrugsRamantamig·Teclistamab

Janssen Research & Development, LLC

Phase 3

400

Arizona, Arkansas, California, Colorado, Connecticut, Florida, Georgia, Illinois

2026-02-04

Recruiting

TRITON-PN: A Study to Evaluate the Efficacy and Safety of Nucresiran in Patients With Hereditary Transthyretin Amyloidosis With Polyneuropathy

NCT07223203Hereditary Transthyretin-Mediated Amyloidosis With Polyneuropathy, hATTR-PN

DrugsNucresiran·Vutrisiran

Alnylam Pharmaceuticals

Phase 3

125

Colorado, Illinois, Maryland, Massachusetts, Minnesota, New York, North Carolina, Tennessee

2026-02-03

Recruiting

A Study to Assess Adverse Events and Change in Disease Activity of Oral Icalcaprant in Adult Participants With Bipolar I or II Disorder

NCT06696755Bipolar I Disorder, Bipolar II Disorder

DrugIcalcaprant

AbbVie

Phase 2

195

Alabama, Arizona, Arkansas, California, Florida, Georgia, Illinois, Missouri

2026-02-03

Active, closed

GATEWAY: Safety Evaluation of the MiniMed™ NMX8-AID System in Children and Adults Living With Diabetes

NCT07228117Type 1 Diabetes Mellitus, Type 2 Diabetes Mellitus

Medtronic MiniMed, Inc.

Not applicable

389

Arkansas, California, Colorado, Connecticut, Florida, Georgia, Idaho, Illinois

2026-02-02

Recruiting

Pharmacokinetics, Safety, and Efficacy of Povorcitinib in Adolescent Participants With Moderate to Severe Hidradenitis Suppurativa

NCT07213973Hidradenitis Suppurativa (HS)

DrugPovorcitinib

Incyte Corporation

Phase 2

Alabama, Arizona, Connecticut, Florida, Georgia, Illinois, Kansas, Kentucky

2026-02-02

Recruiting

Pridopidine Phase 3 Study to Evaluate Efficacy and Safety in ALS

NCT07322003Amyotrophic Lateral Sclerosis

DrugPridopidine

Prilenia

Phase 3

500

Arizona, California, Colorado, Florida, Georgia, Illinois, Kansas, Maryland

2026-02-01

Recruiting

Renal Pelvic Denervation Pilot Trial

NCT07005050Uncontrolled Hypertension

Verve Medical, Inc

Not applicable

Alabama, Arizona, California, Illinois, Iowa, Minnesota, Nevada, Texas

2026-01-30

Recruiting

Study to Evaluate the Safety and Efficacy of Larsucosterol in Participants With Alcohol-associated Hepatitis (AH)

NCT07428538Hepatitis

Bausch Health Americas, Inc.

Phase 3

350

Alabama, Arizona, California, Connecticut, District of Columbia, Florida, Georgia, Illinois

2026-01-29

Recruiting

A Study to Evaluate the Efficacy and Safety of KarXT for the Treatment of Schizophrenia in Adolescents (EMERGENT TEEN)

NCT07288567Schizophrenia

DrugKarXT

Bristol-Myers Squibb

Phase 3

166

California, Florida, Georgia, Illinois, Massachusetts, New York, Ohio, Tennessee

2026-01-29

Recruiting

Study to Assess the Real-World Effectiveness of Ubrogepant in Adult Participants When Treating During the Prodrome Phase of Migraine Attacks

NCT07310290Migraine

AbbVie

Observational

189

California, Illinois, Nebraska

2026-01-27

Recruiting

Flow Detection in Open and Closed Shunt Valve Periods

NCT07478926Hydrocephalus

Rhaeos, Inc.

Not applicable

Illinois

2026-01-27

Recruiting

Study of ABBV-142 to Assess Adverse Events and Change in Disease Activity in Adult Participants With Idiopathic Pulmonary Fibrosis

NCT07230288Idiopathic Pulmonary Fibrosis

AbbVie

Phase 2

165

Alabama, Florida, Illinois, Michigan, Missouri, Pennsylvania, Virginia

2026-01-23

Recruiting

Multicenter Study to Assess the Efficacy and Safety of LB-102 in the Treatment of Adult Patients With BP1MDE.

NCT07494305Bipolar I Disorder

DrugLB-102

LB Pharmaceuticals Inc.

Phase 2

320

Arkansas, California, Florida, Georgia, Illinois, Michigan, Missouri, Nevada

2026-01-23

Recruiting

A Study in Pediatric Participants With Congenital Adrenal Hyperplasia (Balance-CAH)

NCT07159841Congenital Adrenal Hyperplasia, Classic Congenital Adrenal Hyperplasia

DrugAtumelnant

Crinetics Pharmaceuticals Inc.

Phase 2/3

153

California, Illinois, Massachusetts, Michigan, Minnesota, New Jersey, New York, Pennsylvania

2026-01-22

Recruiting

A Maintenance Study to Investigate the Efficacy and Safety of Duvakitug in Participants With Moderately to Severely Active Crohn's Disease

NCT07184944Crohn's Disease

DrugDuvakitug

Sanofi

Phase 3

751

Colorado, Florida, Illinois, Indiana, Louisiana, Missouri, New York, North Carolina

2026-01-22

Recruiting

Inobrodib, Pomalidomide and Dexamethasone in Relapsed or Refractory Multiple Myeloma

NCT07096778Multiple Myeloma Refractory, Multiple Myeloma in Relapse

DrugsPomalidomide·Dexamethasone

CellCentric Ltd.

Phase 2

100

Arizona, California, Florida, Georgia, Illinois, Iowa, Maryland, Massachusetts

2026-01-22

Recruiting

A Study to Investigate Sonrotoclax (BGB-11417) Plus Zanubrutinib (BGB-3111) Compared With Venetoclax Plus Acalabrutinib in Adults With Previously Untreated Chronic Lymphocytic Leukemia

NCT07277231Chronic Lymphocytic Leukemia

DrugsSonrotoclax·Venclyxto·Acalabrutinib·Venclexta

BeOne Medicines

Phase 3

500

California, Colorado, Florida, Illinois, Louisiana, Massachusetts, Minnesota, Nebraska

2026-01-22

Recruiting

A Study to Evaluate the Effect of KarXT on Urological Safety

NCT07221877Schizophrenia

DrugKarXT

Bristol-Myers Squibb

Phase 4

Arkansas, California, Florida, Illinois, Nevada, New Jersey, Pennsylvania, Texas

2026-01-20

Active, closed

A Study of JNJ-95597528 in Participants With Moderate to Severe Atopic Dermatitis

NCT07230860Dermatitis, Atopic

Janssen Research & Development, LLC

Phase 2

189

California, Florida, Illinois, Indiana, Michigan, North Dakota, Oregon, Pennsylvania

2026-01-20

Recruiting

Prospective HemorrhoIdaL EmboliSation (PILES) Registry

NCT07635784Hemorrhoid, Internal Hemorrhoids, Hemorrhoid Bleeding, Hemorrhoidal Bleeding

Joint & Vascular Institute

Observational

1,200

Illinois

2026-01-18

Recruiting

Beamion LUNG-3: Adjuvant Zongertinib vs Standard Treatment in People With Completely Resected Stage II-IIIB NSCLC Harboring Activating HER2 TKD Mutations

NCT07195695Non-small Cell Lung Cancer

DrugsZongertinib·Atezolizumab·Durvalumab·Nivolumab

Boehringer Ingelheim

Phase 3

400

California, District of Columbia, Florida, Georgia, Idaho, Illinois, Massachusetts, Nevada

2026-01-16

Recruiting

Two Part Study of Nenocorilant Combined With Nivolumab in Patients With Advanced Solid Malignancies

NCT07276373Neoplasms

DrugNivolumab

Corcept Therapeutics

Phase 1/2

California, Illinois, Michigan, Texas, Utah

2026-01-16

Recruiting

A Study to Evaluate the Efficacy and Safety of JNJ-88545223 for the Treatment of Participants With Active Psoriatic Arthritis

NCT07321873Arthritis, Psoriatic

Janssen Research & Development, LLC

Phase 2

240

Arkansas, California, Florida, Georgia, Illinois, Indiana, New Mexico, North Carolina

2026-01-15

Active, closed

Horizon 360 Protocol for the Treatment of Paroxysmal Atrial Fibrillation With the Sphere-360™ Catheter and Affera™ Mapping and Ablation System (Horizon 360)

NCT07308847Paroxysmal AF

Medtronic Cardiac Ablation Solutions

Not applicable

300

Arkansas, California, Florida, Georgia, Illinois, Kansas, Massachusetts, Minnesota

2026-01-15

Recruiting

A Study to Investigate Efficacy, Safety and Tolerability of Barzolvolimab Versus Placebo in Adults With Cold Induced Urticaria and Symptomatic Dermographism Inadequately Controlled by H1-antihistamines (EMBARQ - ColdU and SD)

NCT07266402Chronic Inducible Urticaria, Cold Urticaria, Cold-Induced Urticaria, Symptomatic Dermographism

DrugBarzolvolimab

Celldex Therapeutics

Phase 3

240

Alabama, Arizona, California, Florida, Georgia, Idaho, Illinois, Kentucky

2026-01-15

Recruiting

Non-inferiority Study of Frexalimab Subcutaneous Administration Compared to Intravenous Administration in Adult Participants With Multiple Sclerosis

NCT07325292Multiple Sclerosis

DrugsMRI contrast-enhancing preparations·Frexalimab

Sanofi

Phase 3

160

Alabama, Arizona, California, Colorado, Florida, Georgia, Illinois, Maryland

2026-01-14

Recruiting

Fibromyalgia Response With Esreboxetine Evaluated Using a Randomized Withdrawal Research Design

NCT07398417Fibromyalgia

DrugEsreboxetine

Axsome Therapeutics, Inc.

Phase 3

620

Arizona, Arkansas, California, Connecticut, Florida, Georgia, Illinois, Kansas

2026-01-14

Recruiting

A Study to Evaluate the Efficacy and Safety of Veverimer for the Treatment of Metabolic Acidosis

NCT07355062CKD, Metabolic Acidosis

Renibus Therapeutics, Inc.

Phase 3

150

California, Colorado, Delaware, Florida, Georgia, Idaho, Illinois, Indiana

2026-01-13

Recruiting

A Study to Investigate Ronde-cel Versus Investigator's Choice CD19 CAR T-Cell Therapy

NCT07188558Large B-cell Lymphoma, Lymphoma, B-Cell, Relapsed Non-Hodgkin Lymphoma, Refractory Non-Hodgkin Lymphoma

DrugsRondecabtagene autoleucel·Liso-cel·Axi-cel·Lisocabtagene maraleucel

Lyell Immunopharma, Inc.

Phase 3

400

Arizona, Arkansas, California, Colorado, District of Columbia, Florida, Georgia, Illinois

2026-01-12

Active, closed

Efficacy and Safety of Ribupatide Administered Once Weekly in Participants Living With Obesity or Overweight and Diabetes

NCT07284901Obesity With Diabetes, Overweight With Diabetes

DrugRibupatide

Kailera

Phase 3

1,270

Alabama, Arizona, Arkansas, California, Connecticut, Florida, Georgia, Illinois

2026-01-12

Recruiting

Carotid Implants for PreveNtion of STrokE ReCurrEnce From Large Vessel Occlusion in Atrial Fibrillation Patients Treated With Oral Anticoagulation

NCT05723926Atrial Fibrillation, Oral Anticoagulation, Stroke, Implant

Javelin Medical

Not applicable

2,000

Illinois, Massachusetts, New York, Tennessee

2026-01-09

Recruiting

ENV-294 for Moderate-to-Severe Asthma: A 12-Week Study in Adults

NCT07301255Asthma

DrugENV-294

Enveda Therapeutics

Phase 2

Alabama, California, Colorado, Florida, Georgia, Illinois, Kansas, Kentucky

2026-01-09

Recruiting

Study of AZD3632 Monotherapy or in Combination With Anticancer Agents in Participants With Advanced Haematologic Malignancies With KMT2Ar, NPM1m, or Other Genotypes Associated With HOX Overexpression

NCT07155226Acute Lymphoblastic Leukaemia, Acute Myeloid Leukaemia, Higher-risk Myelodysplastic Syndromes

DrugPosaconazole

AstraZeneca

Phase 1/2

Illinois, New York, North Carolina, Oregon, Texas

2026-01-09

Recruiting

Study to Assess the Effects of ALN-ANG3 in Adult Participants With Diabetic Kidney Disease

NCT07271186Diabetic Kidney Disease (DKD)

Regeneron Pharmaceuticals

Phase 2

195

Alabama, Arkansas, California, Connecticut, Florida, Georgia, Illinois, Louisiana

2026-01-09

Recruiting

A Study of AZD0120 in Autoimmune Diseases

NCT07295847Systemic Sclerosis, Idiopathic Inflammatory Myopathies, Rheumatoid Arthritis

DrugAZD0120

AstraZeneca

Phase 1

Arizona, California, Illinois, Michigan, Missouri, New York, North Carolina, Washington

2026-01-09

Recruiting

A Study to Evaluate the Efficacy and Safety of Esketamine for Reduction of Symptoms of Major Depressive Disorder

NCT07227454Depressive Disorder, Major

DrugsEsketamine·Midazolam

Janssen Research & Development, LLC

Phase 3

258

Alabama, District of Columbia, Georgia, Illinois, Maryland, Massachusetts, Minnesota, Ohio

2026-01-08

Active, closed

Study of VYD2311 for the Prevention of COVID-19

NCT07298434COVID-19

Invivyd, Inc.

Phase 3

1,770

California, Florida, Georgia, Illinois, Kansas, Maryland, Massachusetts, Michigan

2026-01-08

Recruiting

An External Control Arm Study in Non-Small Cell Lung Cancer

NCT07174388Non Small Cell Lung Cancer

N-Power Medicine

Observational

650

California, Delaware, Illinois, New Mexico, New York, Pennsylvania, Texas

2026-01-07

Recruiting

Study of Allo-QuadCAR01-T, an Allogeneic CAR-T Targeting CD19/CD20, in Patients With Relapsed or Refractory B-Cell Malignancies

NCT07284433Lymphoma Diffuse Large B-cell, Leukemia and Lymphoma, Leukemia Relapse, Lymphoma Receiving CAR-T Therapy

DrugAllo-QuadCAR01-T

AvenCell Therapeutics, Inc.

Phase 1/2

178

Illinois, Rhode Island, Tennessee, Texas

2026-01-06

Recruiting

Symbiotic-Lung-01 : A Study to Learn About the Study Medicine Called PF-08634404 in Combination With Chemotherapy in Adult Participants With Locally Advanced or Metastatic Non-Small Cell Lung Cancer

NCT07222566Advanced Non-Small Cell Lung Cancer, Non-Small Cell Lung Cancer, Carcinoma, Non-Small-Cell Lung, Carcinoma, Non-Small-Cell Lung (NSCLC)

DrugsPF-08634404·Pembrolizumab

Pfizer

Phase 3

1,410

Arizona, Arkansas, California, Florida, Illinois, Indiana, Louisiana, Maryland

2026-01-06

Recruiting

A Phase 1b, Open-Label Study of DISC-3405 in Participants With Sickle Cell Disease (SCD)

NCT07187973Sickle Cell Disease

DrugDISC-3405

Disc Medicine, Inc

Phase 1

Alabama, California, Georgia, Illinois, Indiana, New York, North Carolina, Ohio

2026-01-06

Recruiting

Comparative Efficacy of Nipocalimab and Efgartigimod in Participants With Generalized Myasthenia Gravis

NCT07217587Myasthenia Gravis

DrugsEfgartigimod·Nipocalimab

Janssen Research & Development, LLC

Phase 3

115

California, Colorado, Connecticut, Florida, Illinois, Indiana, Louisiana, Massachusetts

2026-01-05

Recruiting

A Phase 2 Study of Zelquistinel or Placebo for the Reduction of Symptoms of Major Depressive Disorder

NCT07115329Major Depressive Disorder

DrugZelquistinel

Syndeio Biosciences, Inc

Phase 2

164

Arizona, California, Florida, Georgia, Illinois, Louisiana, Maryland, Massachusetts

2026-01-05

Recruiting

A Study to Compare the Combination of Navlimetostat (BMS-986504) With Pembrolizumab and Chemotherapy Versus Placebo Plus Pembrolizumab and Chemotherapy in First-line Metastatic Non-small Cell Lung Cancer Participants With Homozygous MTAP Deletion

NCT07063745Metastatic Non-small Cell Lung Cancer With MTAP Deletion

DrugsNavlimetostat·Nab-paclitaxel·Pemetrexed·Paclitaxel

Bristol-Myers Squibb

Phase 2/3

590

Alaska, Arizona, Arkansas, California, Delaware, Florida, Idaho, Illinois

2026-01-02

By invitation

Evaluating Whether Intact Fish Skin Graft Can Decrease the Need for Autograft in the Treatment of Deep Partial-Thickness Burns

NCT07326657Partial-thickness Burn Wounds

Kerecis Ltd.

Phase 4

Illinois

2026-01

Recruiting

A Study to Evaluate the Safety and Efficacy of Pumitamig in Combination With Chemotherapy Versus Bevacizumab in Combination With Chemotherapy in Participants With Previously Untreated, Unresectable, or Metastatic Colorectal Cancer

NCT07221357Untreated, Unresectable, or Metastatic Colorectal Cancer

DrugsPumitamig·Folfox·Bevacizumab

Bristol-Myers Squibb

Phase 2/3

990

Arizona, Arkansas, California, Florida, Georgia, Illinois, Indiana, Iowa

2025-12-31

Recruiting

A Study of a Selective ERBB2 Inhibitor (CGT4255), in Patients With Advanced Solid Tumors

NCT07361562Advanced Solid Tumor, Adult, ERBB2 Altered Breast Cancer, ERBB2 Gene Amplification, HER2 Overexpression

Cogent Biosciences, Inc.

Phase 1

100

Arizona, Connecticut, Florida, Illinois, Louisiana, Michigan, Minnesota, Missouri

2025-12-30

Active, closed

Clinical Utility of an Amniotic Membrane Allograft for Diabetic Foot Ulcer Wound Management

NCT06420245Diabetic Foot Ulcer

Legacy Medical Consultants

Not applicable

240

California, Connecticut, Florida, Illinois, Maryland, Oregon

2025-12-30

Active, closed

Efficacy and Safety of Ribupatide Administered Once Weekly Compared With Semaglutide and Placebo in Participants Living With Obesity Who Do Not Have Diabetes

NCT07284979Obesity

DrugsRibupatide·Wegovy·Semaglutide

Kailera

Phase 3

1,270

Arizona, Arkansas, California, Connecticut, Florida, Georgia, Illinois, Kansas

2025-12-30

Active, closed

A Dose-ranging Study to Evaluate the Efficacy, Safety, Pharmacokinetics, and Pharmacodynamics of Galvokimig in Adult Study Participants With Atopic Dermatitis

NCT07277660Atopic Dermatitis

DrugGalvokimig

UCB Biopharma SRL

Phase 2

165

California, Florida, Georgia, Illinois, Indiana, Kentucky, Michigan, Nebraska

2025-12-29

Active, closed

Prescreening Study to Identify Potential Wilson Disease Participants for Gene-Editing Clinical Trial

NCT07226622Wilson Disease

Prime Medicine, Inc.

Observational

California, Connecticut, Illinois, Massachusetts, Michigan, Texas

2025-12-29

Recruiting

A Study to Investigate Efficacy and Safety With SAR445399 in Adult Participants With Moderate to Severe Hidradenitis Suppurativa

NCT07225569Hidradenitis Suppurativa

Sanofi

Phase 2

144

Arizona, California, Florida, Georgia, Illinois, Indiana, Kansas, Kentucky

2025-12-29

Recruiting

AZD5335 vs. Mirvetuximab Soravtansine in FRα-high and AZD5335 vs. Chemotherapy in FRα-low Platinum-resistant Ovarian Cancer

NCT07218809Epithelial Ovarian Cancer

DrugsTorvutatug samrotecan·MIRV·Mirvetuximab Soravtansine·Pegylated liposomal doxorubicin

AstraZeneca

Phase 3

1,100

Alabama, Arkansas, California, District of Columbia, Florida, Illinois, Indiana, Kentucky

2025-12-29

Recruiting

Study to Evaluate Resmetirom in Post-Liver Transplant Patients With MASH

NCT07335601MASH - Metabolic Dysfunction-Associated Steatohepatitis

DrugResmetirom

Madrigal Pharmaceuticals, Inc.

Phase 2

120

California, Colorado, District of Columbia, Illinois, Minnesota, Nebraska, New York, Tennessee

2025-12-29

Recruiting

A Study to Evaluate the Effectiveness of IDCT (Intradiscal Cell Therapy) in Subjects With One Level, Symptomatic Mild to Moderate Lumbar Degenerative Disc Disease

NCT07254806Degenerative Disc Disease

DiscGenics, Inc.

Phase 3

162

Alabama, Arizona, Arkansas, California, District of Columbia, Florida, Idaho, Illinois

2025-12-23

Recruiting

A Study of Mosliciguat in Combination With Inhaled Treprostinil in PH-ILD

NCT07333183Pulmonary Hypertension, Interstitial Lung Disease (ILD), Lung Diseases, Vascular Diseases

DrugMosliciguat

Pulmovant, Inc.

Phase 2

California, Florida, Illinois, Kansas, Massachusetts, Michigan, New Mexico, North Carolina

2025-12-23

Recruiting

Study of ENV-294 in Adults With Moderate-to-Severe Atopic Dermatitis

NCT07298395Atopic Dermatitis (AD)

DrugENV-294

Enveda Therapeutics

Phase 2

105

Alabama, Arkansas, California, Florida, Georgia, Illinois, Indiana, Kentucky

2025-12-22

Recruiting

Phase 2A/B Efficacy and Safety of Dabogratinib in Participants With Low Grade Upper Tract Urothelial Carcinoma

NCT07265947Low Grade Upper Tract Urothelial Carcinoma

DrugTYRA-300

Tyra Biosciences, Inc

Phase 2

230

California, Florida, Georgia, Illinois, Indiana, Massachusetts, Michigan, Missouri

2025-12-22

Recruiting

A Study to Assess Zipalertinib Versus Placebo in Participants With Early Stage NSCLC With Uncommon EGFR Mutations, Following Complete Tumor Resection

NCT07128199Lung Cancer, Adjuvant, Post-surgical, EGFR

DrugZipalertinib

Taiho Oncology, Inc.

Phase 3

360

Alaska, California, District of Columbia, Florida, Georgia, Illinois, Michigan, New Jersey

2025-12-22

Recruiting

Lateral Plantar Artery Embolization For Plantar Fasciitis

NCT07395128Plantar Fasciitis, Chronic, Plantar Fasciitis

Joint & Vascular Institute

Phase 1

Illinois

2025-12-20

Recruiting

Phase 1/2 Study of MZ-1866, an AAV-9 Gene Therapy Delivered by Intracerebroventricular Injection to Participants With Pitt Hopkins Syndrome

NCT07135050Pitt Hopkins Syndrome

Mahzi Therapeutics

Phase 1/2

California, Colorado, Illinois

2025-12-19

Recruiting

A Study of Pasritamig With Docetaxel Versus Docetaxel in Participants With Metastatic Castration-Resistant Prostate Cancer

NCT07225946Prostatic Neoplasms, Castration-Resistant

DrugsPasritamig·Prednisone/Prednisolone·Docetaxel

Janssen Research & Development, LLC

Phase 3

800

Arizona, Arkansas, California, Colorado, Florida, Georgia, Illinois, Kansas

2025-12-19

Recruiting

A Study to Assess the Safety, Tolerability, Efficacy, Pharmacokinetics, and Immunogenicity of Intravenous Administration of ARGX-119 in Pediatric Participants Aged 5 to Less Than 18 Years With Spinal Muscular Atrophy

NCT07287982Spinal Muscular Atrophy (SMA)

DrugARGX-119

argenx

Phase 2

Arkansas, California, Connecticut, Florida, Illinois, Iowa, Maryland, Massachusetts

2025-12-19

Recruiting

A Study to Evaluate the Safety and Effectiveness of the Rapidlink Device When Used in Patients Undergoing an Open Surgical Procedure to Repair the Aorta

NCT07078383Aortic Aneurysm, Aortic Aneurysm and Dissection, Aortic Diseases, Aneurysm of Aorta, Thoracic

Vascutek Ltd.

Not applicable

150

California, Colorado, District of Columbia, Florida, Illinois, Maryland, Massachusetts, Missouri

2025-12-19

Recruiting

Study Evaluating the Safety and Efficacy of HWK-007, a PTK7-directed Antibody Drug Conjugate in Participants With Advanced Solid Tumors

NCT07444814Endometrial Cancer, Ovarian Cancer, Ovarian Cancer Metastatic, Ovarian Cancer Metastatic Recurrent

Whitehawk Therapeutics, Inc.

Phase 1

226

Arkansas, California, Illinois, Michigan, New Jersey, New York, Ohio, Texas

2025-12-19

Recruiting

Open-Label Phase 1/2 Study of NEO-811 in Subjects With Locally Advanced or Metastatic Non-Resectable Clear Cell Renal Cell Carcinoma

NCT07300241Clear Cell Renal Cell Carcinoma, Renal Cell Carcinoma, RCC, Clear Cell Renal Cell Carcinoma Metastatic

Neomorph, Inc

Phase 1

California, Connecticut, Florida, Illinois, Michigan, Nebraska, New York, Ohio

2025-12-19

Recruiting

A Clinical Study of Islatravir and Ulonivirine for People With HIV-1 Who Have Not Been Treated Before (MK-8591B-062)

NCT07266831Human Immunodeficiency Virus Type 1 (HIV-1) Infection

DrugB/F/TAF

Merck Sharp & Dohme LLC

Phase 2/3

570

California, Colorado, District of Columbia, Florida, Georgia, Illinois, Michigan, Missouri

2025-12-18

Active, closed

Efficacy and Safety of Ribupatide in Participants Living With Obesity or Overweight With Weight-Related Comorbidities Who Do Not Have Diabetes

NCT07284875Obesity, Overweight

DrugRibupatide

Kailera

Phase 3

2,530

Alabama, Arizona, California, Colorado, Connecticut, Florida, Georgia, Illinois

2025-12-18

Recruiting

A Study to Assess Change in Disease Activity and Adverse Events of Oral Icalcaprant in Adult Participants With Major Depressive Disorder

NCT07276997Major Depressive Disorder

DrugIcalcaprant

AbbVie

Phase 2

195

Alabama, Arizona, Arkansas, California, Florida, Georgia, Illinois, Nevada

2025-12-18

Recruiting

A Phase 1 Study to Evaluate the Safety and Pharmacokinetics of ABBV-243 in Healthy Adults.

NCT07306754Healthy Volunteers

AbbVie

Phase 1

Illinois

2025-12-17

Recruiting

A Real-world Chronic Myelogenous Leukemia (CML) Patient Disease Registry to Describe Patient Experience and Clinical Outcomes Among Patients With CML Receiving Approved First or Second Line Tyrosine Kinase Inhibitor (TKI) Therapy

NCT07091019Chronic Myelogenous Leukemia - Chronic Phase

Novartis Pharmaceuticals

Observational

1,000

Alabama, California, Connecticut, Florida, Illinois, Maryland, Missouri, New York

2025-12-17

Recruiting

Study to Evaluate Efficacy and Safety of Firmonertinib Compared With Investigator's Choice of EGFR Inhibitor as First-Line Treatment in Participants Who Have Locally Advanced or Metastatic NSCLC With EGFR P-Loop and Alpha C-Helix Compressing (PACC) Uncommon Mutations

NCT07185997Non-Small-Cell Lung Cancer, Metastatic Non-Small-Cell Lung Cancer, Advanced Non-Small-Cell Lung Cancer, EGFR P-Loop and Alpha C-Helix Compressing

DrugFurmonertinib

ArriVent BioPharma, Inc.

Phase 3

480

California, Colorado, Illinois, Michigan, New York, Ohio, Pennsylvania, Texas

2025-12-17

Recruiting

Study of DONQ52 in Active Celiac Disease

NCT07239336Celiac Disease

Chugai Pharmaceutical

Phase 2

Alabama, Arizona, California, Colorado, Connecticut, Florida, Illinois, Louisiana

2025-12-16

Recruiting

A Study to Investigate Efficacy and Safety of AZD1163 in Participants With Rheumatoid Arthritis

NCT07276581Rheumatoid Arthritis

AstraZeneca

Phase 2

320

Arizona, California, Colorado, Florida, Georgia, Illinois, Louisiana, Maryland

2025-12-15

Recruiting

Study of ASP2957 in Male Participants With X-linked Myotubular Myopathy Who Need Ventilators

NCT07052929X-Linked Myotubular Myopathy

DrugsSirolimus·Methylprednisolone·Prednisolone

Astellas Gene Therapies

Phase 1/2

Illinois, Massachusetts, Oregon, Texas

2025-12-15

Recruiting

A Study of a Thyroid Hormone Receptor Beta Isoform (THRβ) Agonist and an Semicarbazide Sensitive Amine Oxidase (SSAO) Inhibitor, Alone and in Combination, in Adults With Presumed Metabolic Dysfunction-associated Steatohepatitis (MASH)

NCT07288138Metabolic Dysfunction-associated Steatohepatitis

DrugsECC0509·ECC4703

Eccogene

Phase 2

160

Arizona, Arkansas, California, Florida, Georgia, Illinois, Indiana, Louisiana

2025-12-15

Recruiting

NV PSR INSPIRE-A Pipeline™ Vantage Post Approval Study

NCT06604884Intracranial Aneurysm

Medtronic Neurovascular Clinical Affairs

Observational

118

Florida, Georgia, Illinois, Indiana, Iowa, Michigan, Missouri, South Carolina

2025-12-12

Active, closed

A Study to Evaluate the Effect of Obicetrapib/Ezetimibe 10 mg Fixed-Dose Combination or Obicetrapib 10 mg Daily on Top of Guideline-Recommended Lipid-Lowering Therapy in Participants With Type 2 Diabetes and/or Metabolic Syndrome

NCT07219602Lipidemia, Type 2 Diabetes (T2DM), Metabolic Syndrome (MetS)

DrugsEzetimibe FDC·Obicetrapib

NewAmsterdam Pharma

Phase 3

300

Arizona, California, Florida, Idaho, Illinois, Kentucky, Maine, Maryland

2025-12-11

Recruiting

A Study to Evaluate Atumelnant in Adults With Congenital Adrenal Hyperplasia

NCT07144163Congenital Adrenal Hyperplasia, Classic Congenital Adrenal Hyperplasia

DrugAtumelnant

Crinetics Pharmaceuticals Inc.

Phase 3

150

California, Colorado, Florida, Georgia, Illinois, Maryland, Michigan, Minnesota

2025-12-11

Recruiting

Study of Choline Chloride for Injection in Adolescent and Adult Patients With Intestinal Failure Receiving Long Term Parenteral Support

NCT06910943Choline Deficiency, Liver Injury

Protara Therapeutics

Phase 2/3

129

Colorado, Florida, Illinois, Nebraska, New York, North Carolina, Ohio, Texas

2025-12-10

Recruiting

A Study of a Deuterated Psilocin Analog (CYB003) in Humans With Major Depressive Disorder

NCT06793397Major Depressive Disorder (MDD), Depression in Adults, Depression - Major Depressive Disorder, Depression Disorders

DrugCYB003

Cybin IRL Limited

Phase 3

330

Alabama, Arizona, Arkansas, California, Connecticut, Florida, Georgia, Illinois

2025-12-10

Recruiting

ASPEN-09-03: A Study of Evorpacept in Combination With Trastuzumab and Chemotherapy in Metastatic HER2-Positive Breast Cancer

NCT07007559Breast Cancer, Metastatic

DrugsEvorpacept·Herceptin·Eribulin·Vinorelbine

ALX Oncology Inc.

Phase 2

120

Arizona, California, Colorado, District of Columbia, Florida, Illinois, Michigan, Minnesota

2025-12-10

Recruiting

A Study to Learn if Bimekizumab Given in Different Ways is Safe and Moves Similarly Throughout the Body Over Time in Adults

NCT07290036Psoriatic Arthritis, Axial Spondyloarthritis

UCB Biopharma SRL

Phase 1

392

Arizona, California, Colorado, Florida, Illinois, Michigan, New Jersey, New Mexico

2025-12-10

Recruiting

A Study to Learn About a Clostridioides Difficile Vaccine in People 65 Years of Age and Older

NCT07282665Clostridoides Difficile Associated Disease

Pfizer

Phase 3

32,500

Alabama, Arizona, Arkansas, California, District of Columbia, Florida, Georgia, Illinois

2025-12-10

Recruiting

Prevention of Recurrent C. Difficile Infection Study With AZD5148 Monoclonal Antibody

NCT07285213Clostridioides Difficile Infection

AstraZeneca

Phase 2

230

Arizona, California, Connecticut, Florida, Georgia, Idaho, Illinois, Kentucky

2025-12-10

Recruiting

Study to Evaluate INCB123667 Versus Investigator's Choice of Chemotherapy in Participants With Platinum-Resistant Ovarian Cancer With Cyclin E1 Overexpression

NCT07214779Ovarian Cancer

DrugINCB123667

Incyte Corporation

Phase 3

466

Alaska, Arizona, California, Colorado, Florida, Georgia, Illinois, Kentucky

2025-12-09

Active, closed

A Study to Find Out How EMPAgliflozin is Tolerated and if it Helps Children and Adolescents With Chronic KIDNEY Disease (EMPA-KIDNEY® Kids)

NCT07107945Chronic Kidney Disease

DrugDapagliflozin

Boehringer Ingelheim

Phase 3

135

Alabama, California, Florida, Georgia, Illinois, Indiana, Kentucky, Maryland

2025-12-09

Recruiting

A Study of Solbinsiran (LY3561774) in Participants With Severe Hypertriglyceridemia

NCT07269210Severe Hypertriglyceridemia

Eli Lilly and Company

Phase 2

Arizona, California, Connecticut, Florida, Illinois, Indiana, Kentucky, Maryland

2025-12-08

Active, closed

Phase 2 Study of SAT-3247 in Pediatric Ambulatory Patients

NCT07287189Duchenne Muscular Dystrophy, Duchenne, DMD, Neuromuscular Diseases

DrugSAT-3247

Satellos Bioscience, Inc.

Phase 2

California, Colorado, Illinois, Massachusetts, Missouri, Ohio, Washington

2025-12-08

Recruiting

Optimize Pattern Recognition Control of Powered Upper Limb Prosthesis

NCT07850544Prosthesis User, Prosthesis, Prosthetic, Upper Limb Amputation

Liberating Technologies, Inc.

Not applicable

Illinois, Massachusetts

2025-12-05

Active, closed

A Phase IIb Study to Evaluate the Effect of Dapagliflozin in Combination With Baxdrostat Compared With Baxdrostat on Albuminuria in Participants With Chronic Kidney Disease and High Blood Pressure.

NCT07222917Chronic Kidney Disease and Hypertension

DrugBaxdrostat/dapagliflozin

AstraZeneca

Phase 2

222

Arizona, Florida, Georgia, Illinois, Kansas, North Carolina, Ohio, Pennsylvania

2025-12-05

Recruiting

A Study to Assess the Efficacy and Safety of RO7790121 in Participants With Moderate to Severe Rheumatoid Arthritis Who Have Not Responded to or Who Cannot Tolerate Tumor Necrosis Factor (TNF) and/or Janus Kinase (JAK Inhibitors)

NCT07137598Rheumatoid Arthritis

DrugAfimkibart

Hoffmann-La Roche

Phase 2

160

Arizona, California, Florida, Illinois, Louisiana, Michigan, New York, Ohio

2025-12-05

Recruiting

A Long-Term Study of Zasocitinib in Children and Teenagers With Plaque Psoriasis

NCT07250802Plaque Psoriasis

DrugZasocitinib

Takeda

Phase 3

110

California, Florida, Illinois, Ohio, South Carolina, Texas, Wisconsin

2025-12-04

Recruiting

Evaluating the Efficacy of OCM™ (Omeza® Complete Matrix) in the Treatment of Diabetic Foot Ulcers

NCT07161830Diabetic Foot Ulcer

Omeza, LLC

Not applicable

180

Illinois, Louisiana, Mississippi, Ohio

2025-12-04

Recruiting

A Study of Praliciguat in Participants With Focal Segmental Glomerulosclerosis (FSGS)

NCT07268638Focal Segmental Glomerulosclerosis

Akebia Therapeutics

Phase 2

California, Colorado, Florida, Georgia, Illinois, Kentucky, Massachusetts, Michigan

2025-12-03

Recruiting

A Study of IDRX-42 (GSK6042981) Versus (vs) Sunitinib in Participants With Gastrointestinal Stromal Tumors After Imatinib Therapy

NCT07218926Gastrointestinal Neoplasms

DrugsIDRX-42·Sunitinib

GlaxoSmithKline

Phase 3

450

Arizona, California, Colorado, Connecticut, District of Columbia, Florida, Illinois, Iowa

2025-12-03

Recruiting

A Study of Amivantamab in Addition to Standard of Care Agents (SOC) Compared With SOC Alone in Participants With Recurrent/Metastatic Head and Neck Cancer

NCT07276399Squamous Cell Carcinoma of Head and Neck

DrugsAmivantamab·Cisplatin·Carboplatin·Pembrolizumab

Janssen Research & Development, LLC

Phase 3

500

Arizona, California, Connecticut, Florida, Georgia, Illinois, Kentucky, Maryland

2025-12-03

Recruiting

A Study to Investigate GB-0895 Adjunctive Therapy in Adults and Adolescents With Severe Uncontrolled Asthma (SOLAIRIA-1)

NCT07276724Severe Asthma

DrugGB-0895

Generate Biomedicines

Phase 3

786

California, Colorado, Florida, Georgia, Illinois, Maryland, Michigan, Mississippi

2025-12-03

Active, closed

Dose Ranging Study of ORKA-001 in Patients With Moderate-to-Severe Plaque Psoriasis

NCT07290569Plaque Psoriasis

DrugORKA-001

Oruka Therapeutics, Inc.

Phase 2

160

Arizona, Arkansas, California, Florida, Illinois, Indiana, Maryland, New York

2025-12-03

Active, closed

Study to Evaluate HM15275 in Obese or Overweight Subjects Without Diabetes Mellitus

NCT07205900Obese, Obesity

DrugHM15275

Hanmi Pharmaceutical Company Limited

Phase 2

267

California, Illinois, Iowa, North Carolina, South Carolina, Tennessee, Texas

2025-12-02

Active, closed

A Study of DII235 in Adults With Elevated Lipoprotein(a)

NCT07235046Lipoprotein Disorder

Novartis Pharmaceuticals

Phase 2

234

Alabama, Arkansas, California, Florida, Georgia, Illinois, Louisiana, Maryland

2025-12-02

Recruiting

Symbiotic-GI-13: A Study to Learn About Study Medicine Called PF-08634404 as a Single Treatment and Combination Treatment in Adult Participants With a Liver Cancer Called Hepatocellular Carcinoma, That is Too Advanced to be Removed by Surgery and May Have Spread to Other Parts of the Body.

NCT07227012Carcinoma, Hepatocellular, Hepatocellular Cancer, Hepatocellular Carcinoma, Unresectable Hepatocellular Carcinoma

DrugsPF-08634404·Yervoy·Ipilimumab

Pfizer

Phase 1/2

138

California, Florida, Illinois, Minnesota, Missouri, Nevada, North Carolina, Ohio

2025-12-01

Recruiting

Post-market Safety and Effectiveness of the CORUS-LX System in Improving Lumbar Interbody Fusion Outcomes

NCT07222787Radiculopathy Lumbar, Degenerative Lumbar Disc Disease

Providence Medical Technology, Inc.

Not applicable

250

Arizona, California, Illinois, New York, North Carolina, Ohio, Texas, Utah

2025-12-01

Recruiting

A Study to Assess Adverse Events and Change in Disease Activity in Participants 12 Years of Age or Older With Locally Advanced or Metastatic Solid Tumors That Harbor MET Amplification Receiving Intravenously Infused Telisotuzumab Adizutecan

NCT07196644Solid Tumors Harboring MET Amplification

DrugTelisotuzumab Adizutecan

AbbVie

Phase 2

100

California, Connecticut, Florida, Illinois, Michigan, New York, North Carolina, Tennessee

2025-12-01

Recruiting

Prenatal Study in Healthy Pregnant Women

NCT07226414Pregnancy

Perelel Inc.

Not applicable

Illinois

2025-12-01

Recruiting

A Study of ZL-1310 Versus Investigator's Choice of Therapy in Participants With Relapsed Small Cell Lung Cancer (DLLEVATE)

NCT07218146Small-cell Lung Cancer

DrugZL-1310

Zai Lab (Shanghai) Co., Ltd.

Phase 3

480

California, Colorado, Connecticut, Florida, Illinois, Iowa, Kentucky, Maryland

2025-11-30

Recruiting

Study of Reformulated Levulan Kerastick Plus PDT for Actinic Keratosis on Upper Extremities

NCT07144852Actinic Keratosis

Sun Pharmaceutical Industries, Inc.

Phase 3

260

Arizona, California, Colorado, Florida, Idaho, Illinois, Indiana, Minnesota

2025-11-29

Recruiting

Trial Against INtractable Type 2 Diabetes (CAPTAIN-T2D)

NCT07296484Type 2 Diabetes, Cortisol Excess

DrugClofutriben

Sparrow Pharmaceuticals

Phase 2

1,500

Arizona, California, Florida, Georgia, Idaho, Illinois, Iowa, Kansas

2025-11-29

Recruiting

A Study to Evaluate LY3537021 for the Treatment of Nausea and Vomiting Caused by Chemotherapy in Adults With Cancer

NCT07169851Nausea, Vomiting, Drug-Related Side Effects and Adverse Reactions, Neoplasms

Eli Lilly and Company

Phase 2

204

California, Colorado, Florida, Georgia, Illinois, Indiana, Mississippi, New York

2025-11-28

Recruiting

Study to Assess the Efficacy and Safety of Rina-S Compared to Treatment of Investigator's Choice in Participants With Endometrial Cancer

NCT07166094Endometrial Cancer, Recurrent or Progressive Endometrial Cancer

DrugRina-S

Genmab

Phase 3

660

Alabama, Arizona, California, Connecticut, District of Columbia, Florida, Georgia, Illinois

2025-11-28

Recruiting

A Study of Xaluritamig Plus Abiraterone Versus Investigator's Choice in Participants With Chemotherapy-naïve Metastatic Castration-resistant Prostate Cancer

NCT07213674Metastatic Castration-resistant Prostate Cancer

DrugsXaluritamig·Cabazitaxel·Abiraterone acetate·Docetaxel

Amgen

Phase 3

750

Arizona, California, Colorado, Connecticut, Delaware, Florida, Georgia, Illinois

2025-11-28

Recruiting

A Study to Assess Adverse Events, Change in Disease Activity and How Intravenous (IV) ABBV901 Moves Through the Body Alone or in Combination With Other Anticancer Drugs in Adult Participants With Ovarian Cancer

NCT07278336Ovarian Cancer

DrugsBevacizumab·Carboplatin

AbbVie

Phase 1

285

California, Colorado, Illinois, Nebraska, Texas, Utah, Virginia

2025-11-27

Recruiting

A Study to Assess the Efficacy and Safety of Debio 4126 in Participants With Acromegaly Previously Treated With Somatostatin Analogs

NCT06930625Acromegaly

Debiopharm International SA

Phase 3

119

California, Illinois, Massachusetts, Missouri, Nevada, New York, Ohio, Oregon

2025-11-26

Recruiting

A Study to Evaluate the Efficacy and Safety of Cannabidiol Oral Solution (CBD-OS [GWP42003-P, JZP926]) for the Treatment of Focal-Onset Seizures

NCT07233239Focal Seizures

DrugCannabidiol

Jazz Pharmaceuticals

Phase 1

100

Arizona, California, Connecticut, Florida, Georgia, Illinois, Maryland, Michigan

2025-11-26

By invitation

Observational Study of VYKAT™ XR in Patients With Prader-Willi Syndrome

NCT07450664Prader-Willi Syndrome

Soleno Therapeutics, Inc.

Observational

200

Arizona, California, Colorado, Florida, Georgia, Illinois, Indiana, Massachusetts

2025-11-26

Recruiting

Detrusor Nerve Radiofrequency Ablation for Overactive Bladder in Women

NCT07209397Overactive Bladder, Overactive Bladder (OAB), Urge Urinary Incontinence, Mixed Urinary Incontinence (Urge-Predominant)

InMode MD Ltd.

Not applicable

202

California, District of Columbia, Idaho, Illinois, Kansas, Massachusetts, Nebraska, Nevada

2025-11-25

By invitation

Long-term Efficacy and Safety Extension (LTE) Study of Barzolvolimab in Participants With Chronic Spontaneous Urticaria

NCT07256392Chronic Spontaneous Urticaria

DrugBarzolvolimab

Celldex Therapeutics

Phase 3

1,370

Alabama, Arizona, California, Colorado, Florida, Georgia, Illinois, Indiana

2025-11-25

Active, closed

Taldefgrobep Alfa in Adults With Overweight and Obesity

NCT07281495Obesity, Overweight

DrugTaldefgrobep alfa

Biohaven Therapeutics Ltd.

Phase 2

150

California, Florida, Illinois, Indiana, Louisiana, Missouri, North Carolina, North Dakota

2025-11-24

Recruiting

REGN7508 Versus Acetylsalicylic Acid (ASA) for Venous Thromboprophylaxis After Total Knee Arthroplasty in Adult Participants

NCT07213778Symptomatic Venous Thromboembolism (VTE)

DrugsCenvacibart·Acetylsalicylic acid

Regeneron Pharmaceuticals

Phase 3

2,000

California, Colorado, Florida, Illinois, Indiana, Kansas, Maryland, Massachusetts

2025-11-24

Active, closed

A Study to Evaluate How the Study Drug Moves Through the Body, Adverse Events, and How the Body Tolerates ABBV-547 Injections

NCT07232004Healthy Volunteer, Psoriasis

AbbVie

Phase 1

142

Alabama, Arkansas, California, Florida, Illinois, Massachusetts, Minnesota, Missouri

2025-11-24

Active, closed

A Study of KT-621 Administered Orally to Participants With Moderate to Severe Atopic Dermatitis

NCT07217015Atopic Dermatitis

DrugKT-621

Kymera Therapeutics, Inc.

Phase 2

200

Alabama, Arkansas, California, Florida, Illinois, Michigan, New York, North Dakota

2025-11-24

Recruiting

Study of MRM-3379 in Male Participants With Fragile X Syndrome (BLOOM)

NCT07209462Fragile X Syndrome

Mirum Pharmaceuticals, Inc.

Phase 2

Arizona, California, Colorado, Florida, Georgia, Illinois, Maryland, Massachusetts

2025-11-22

Recruiting

A Study to Assess Anti-Tumor Activity of Intravenously (IV) Infused Carboplatin With Mirvetuximab Soravtansine in Participants With Newly Diagnosed Folate Receptor Alpha (FRα)Expressing Advanced-Stage Serous Epithelial Ovarian, Fallopian Tube or Primary Peritoneal Cancer.

NCT06890338Epithelial Ovarian Cancer, Fallopian Tube Cancer, Primary Peritoneal Cancer, Neoadjuvant

DrugsMIRV·Mirvetuximab Soravtansine·Bevacizumab·Carboplatin

AbbVie

Phase 2

140

Alabama, California, Connecticut, Florida, Illinois, Indiana, Kentucky, Louisiana

2025-11-21

Recruiting

Phase 4 Study: Long-term Safety and Efficacy of NT-501 in MacTel Type 2, Including Sham Procedure Participants

NCT06971939Macular Telangiectasia Type 2 (MacTel)

Neurotech Pharmaceuticals

Phase 4

234

California, Colorado, Florida, Georgia, Illinois, Maryland, Massachusetts, Michigan

2025-11-21

Recruiting

A Study to Assess the Adverse Events, Change in Disease Activity, and How Oral ABBV-711 Tablets Move Through the Body as a Monotherapy and in Combination With Intravenously Infused Budigalimab (ABBV-181), in Adults With Advanced Squamous Tumors

NCT07241039Advanced Squamous Tumors

DrugBudigalimab

AbbVie

Phase 1

220

California, Illinois, Michigan, North Carolina, Texas

2025-11-20

Recruiting

A Study of ABBV-295 Subcutaneous Injections to Assess Adverse Events and Pharmacokinetics in Adult Participants With Obesity

NCT07291232Obesity

DrugABBV-295

AbbVie

Phase 1

California, Illinois

2025-11-19

Recruiting

Study of Reformulated Levulan Kerastick Plus PDT for Actinic Keratosis on Face and Scalp

NCT07144345Actinic Keratosis

Sun Pharmaceutical Industries, Inc.

Phase 3

160

California, Florida, Illinois, Indiana, Minnesota, Missouri, Oregon, South Carolina

2025-11-19

Active, closed

Phase 2a Study of VX-407 in Participants With ADPKD Who Have a Subset of PKD1 Gene Variants (AGLOW)

NCT07161037Autosomal Dominant Polycystic Kidney Disease (ADPKD)

DrugVX-407

Vertex Pharmaceuticals Incorporated

Phase 2

Alabama, California, Connecticut, Florida, Georgia, Illinois, Iowa, Kansas

2025-11-19

Active, closed

A Study of Retatrutide (LY3437943) in Participants With Obesity or Overweight

NCT07232719Obesity, Overweight

DrugRetatrutide

Eli Lilly and Company

Phase 3

250

California, Florida, Illinois, Kentucky, Louisiana, Maryland, Missouri, New Jersey

2025-11-17

Active, closed

Extended Release Protein Dosing

NCT07313436Nutrition

VitaKey Inc.

Not applicable

Illinois

2025-11-17

Recruiting

This Study is a Non-interventional Disease Registry of Adolescent and Adult Patients With Atopic Dermatitis Who Initiate or Switch Any Systemic Treatment

NCT07290803Atopic Dermatitis

Sanofi

Observational

1,000

Alabama, Arizona, California, Colorado, Florida, Georgia, Illinois, Michigan

2025-11-17

Active, closed

A 16-Week Study to Learn About the Study Medicine Called Ritlecitinib in Adults With Long Lasting Painful Red Skin Lumps, Known by the Medical Term, Hidradenitis Suppurativa, or HS.

NCT07228390Hidradenitis Suppurativa

DrugRitlecitinib

Pfizer

Phase 2

128

Arizona, Arkansas, California, Florida, Georgia, Illinois, Indiana, Kansas

2025-11-13

Recruiting

A Study to Investigate the Safety and Preliminary Efficacy of ALLO-329, an Allogeneic CAR T-cell Therapy, in Adults With Autoimmune Disease

NCT07085104Systemic Lupus Erythematosus (With and Without Nephritis), Idiopathic Inflammatory Myopathy, Systemic Sclerosis

DrugsFludarabine·Cyclophosphamide

Allogene Therapeutics

Phase 1

Arizona, California, Colorado, Florida, Illinois, Iowa, Kansas, Kentucky

2025-11-13

Active, closed

Probiotics in Adults With Rheumatoid Arthritis

NCT07304505Rheumatoid Arthritis (RA)

Ancilia Biosciences

Not applicable

Illinois

2025-11-13

Recruiting

Study of AZD4512 Monotherapy or in Combination With Anticancer Agents in Participants With Acute Lymphoblastic Leukemia

NCT07109219B-cell Acute Lymphoblastic Leukemia (B-ALL)

AstraZeneca

Phase 1/2

California, Florida, Illinois, Iowa, Tennessee, Texas

2025-11-12

Recruiting

A Study of NNZ-2591 in Pediatric Participants With Phelan-McDermid Syndrome

NCT07281079Phelan-McDermid Syndrome

DrugNNZ-2591

Neuren Pharmaceuticals Limited

Phase 3

160

Alabama, California, District of Columbia, Georgia, Illinois, Maryland, Massachusetts, Michigan

2025-11-12

Active, closed

A Clinical Trial of Trontinemab in Participants With Early Symptomatic Alzheimer's Disease

NCT07170150Alzheimers Disease

DrugTrontinemab

Hoffmann-La Roche

Phase 3

1,060

Arizona, California, Connecticut, Florida, Georgia, Illinois, Massachusetts, Michigan

2025-11-12

Active, closed

A Clinical Study of Enlicitide in Participants With High Cholesterol (MK-0616-037)

NCT07216482Hyperlipidemia

DrugsEnlicitide·Enlicitide Decanoate·Rosuvastatin

Merck Sharp & Dohme LLC

Phase 3

996

Alabama, Arizona, California, Colorado, Florida, Illinois, Indiana, Kansas

2025-11-11

Recruiting

Assessment of CSF Shunt Flow During Activities of Daily Living and Sleep With a Thermal Measurement Device

NCT07050628Hydrocephalus

Rhaeos, Inc.

Not applicable

Illinois, Virginia

2025-11-10

Recruiting

LY4268989 (MORF-057) Co-Administered With Mirikizumab in Adults With Moderately to Severely Active Ulcerative Colitis:

NCT07186101Ulcerative Colitis

DrugsZotemtegrast·Mirikizumab

Eli Lilly and Company

Phase 2

252

Arizona, California, Colorado, Florida, Illinois, Indiana, Kentucky, Massachusetts

2025-11-10

Recruiting

Evaluation of ELU42 Topical Spray for the Treatment of Diabetic Foot Ulcers

NCT07396376Diabetic Foot Ulcer, Wagner Grade 1 - 2, Chronic Wound, Open Wound

Eluciderm Inc

Phase 1/2

Illinois, New Jersey, Texas

2025-11-10

Recruiting

Safety and Effectiveness of the BrainsWay Deep Transcranial Magnetic Stimulation (Deep TMS) for Treatment and Reduction of Heavy Drinking in Individuals With of Alcohol Use Disorder (AUD)

NCT07216872Alcohol Use Disorder, Alcoholism, Alcohol Abuse, Alcohol Dependence

Brainsway

Not applicable

186

Alabama, California, Florida, Illinois, New York, Ohio, Oregon, West Virginia

2025-11-07

Recruiting

A Study of the Efficacy and Safety of Lisocabtagene Maraleucel (Liso-cel) as First-Line Therapy in Adults With Transplant-Ineligible Primary Central Nervous System Lymphoma

NCT07015242Lymphoma

DrugsProcarbazine·Liso-cel·Lisocabtagene maraleucel·Calcium folinate

Juno Therapeutics, Inc., a Bristol-Myers Squibb Company

Phase 2

Colorado, Florida, Illinois, Massachusetts, Missouri, New Jersey, New York, Ohio

2025-11-06

Recruiting

A Study to Learn About the Study Medicine PF-08052667 in People With Bladder Cancer

NCT07206225Non-muscle Invasive Bladder Cancer

DrugSasanlimab

Pfizer

Phase 1

294

Alabama, Florida, Georgia, Illinois, Iowa, Kansas, New Jersey, New York

2025-11-06

Recruiting

Study to Assess the Injection Burden, Adverse Events, Change in Disease Activity, and Long-Term Preservation of Visual Acuity of Surabgene Lomparvovec in Adult Participants With Neovascular Age-Related Macular Degeneration (nAMD)

NCT07007065Neovascular Age-related Macular Degeneration

DrugSurabgene Lomparvovec

AbbVie

Phase 3

561

Arizona, California, Colorado, Florida, Georgia, Illinois, Indiana, Iowa

2025-11-05

Recruiting

Study of Izalontamab Brengitecan (BMS-986507) Versus Platinum-Pemetrexed for EGFR-mutated Non-small Cell Lung Cancer After Failure of EGFR TKI Therapy (IZABRIGHT-Lung01)

NCT07100080Non-Small Cell Lung Cancer

DrugsIza-bren·Pemetrexed·Cisplatin·Carboplatin

Bristol-Myers Squibb

Phase 2/3

500

California, Colorado, Florida, Georgia, Illinois, Massachusetts, Missouri, Nevada

2025-11-05

Cite this view

Priya Life Science (2026). Clinical trial register: industry-sponsored studies with a US investigative site, filtered. Derived from ClinicalTrials.gov. Retrieved 16 October 2026. https://priyalifescience.com/clinical-trials-usa/state/illinois

Query this register directly

GET /api/trials?country=usa&status=recruiting&format=json Try it now →

About this register

This register is built from ClinicalTrials.gov, the trial registry run by the U.S. National Library of Medicine. It includes every industry-sponsored study on the registry that lists at least one investigative site in the US and is recruiting, not yet recruiting, active but no longer recruiting, or enrolling by invitation: 9,144 studies in total at the last sync on 16 Oct 2026, 03:16 UTC. Academic and other non-industry sponsors are out of scope by design. The full list can be downloaded as CSV or queried as JSON through the register API.

This page shows the 2,491 of those studies with a site in Illinois.

How many clinical trials are recruiting in Illinois?

1,263 of the 2,491 studies on this page are recruiting new participants as of the 16 Oct 2026, 03:16 UTC sync. A further 33 have not yet opened recruitment, 1,133 are active but closed to new participants, and 62 are enrolling by invitation only. Eligibility for any study is decided by its study team.

Summary by phase

Studies by phase (Illinois), 2,491 studies
Phase	Studies	Recruiting	Share
Phase 3	871	397	35%
Phase 2	475	231	19.1%
Not applicable	331	155	13.3%
Observational	266	145	10.7%
Phase 1	208	129	8.4%
Phase 1/2	199	125	8%
Phase 2/3	90	52	3.6%
Phase 4	50	29	2%
Early Phase 1	1	0	0%

Most active sponsors

Lead sponsors with the most studies (Illinois)
Lead sponsor	Studies	Recruiting
AstraZeneca	108	58
AbbVie	102	49
Eli Lilly and Company	69	44
Merck Sharp & Dohme LLC	63	32
Novartis Pharmaceuticals	63	25
Janssen Research & Development, LLC	56	24
Bristol-Myers Squibb	51	30
Pfizer	51	33
Hoffmann-La Roche	43	14
Sanofi	39	20

Listing here is informational and not medical advice; eligibility is determined by each study team. Compare pay for the teams running these studies in the US Pharma Salary Guide, see who's behind them in the US Company Directory, or track approvals on the FDA Approvals Tracker. For Irish, UK and EU sites, see the Ireland, UK and EU registers.